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Abstract
1.1 Objectives
This thesis reviews the technique of meta analysis 
applied to randomised controlled trials in medicine and 
employs the new technique of mixed models to account for 
heterogeneity of effects amongst trials. Mixed models 
are used to analyse the survival benefits of 
angiotensin-converting enzyme (ACE) inhibitors commenced 
within 16 days of myocardial infarction. Optimum 
treatment population, regime and duration of treatment 
are addressed. The treatment group receives an ACE 
inhibitor in addition to standard treatment whereas the 
control group receives standard treatment only.
My interest in this project was inspired by my work in 
drug evaluation, an area in which meta analysis is 
becoming more important.
1.2 Data Sources
Published trials were identified by a systematic search 
of Medline, Embase, Current Contents, Dialog, Biosis and 
Scisearch, and bibliographies from reviews and clinical 
trial reports. An attempt to identify unpublished trials 
was made by discussions with colleagues; however, none 
were found.
1.3 Data Selection
Fourteen randomised placebo-controlled trials involving 
107,005 subjects were included in the analyses.
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1.4 Data Extraction
Data were extracted from the trial reports by the 
author.
1.5 Data Synthesis
The outcomes of interest were cardiovascular deaths and 
total deaths. Pooled odds ratios were obtained using a 
mixed logistic regression model with trial as a random 
effect and treatment as a fixed effect. There was 
significant heterogeneity of effect amongst trials; 
thus, the mixed model approach was appropriate. The 
mixed model was then used to examine trial covariates. 
For all-cause deaths, the mixed model demonstrated that 
significant factors in the heterogeneity of effect 
amongst trials were time of commencing treatment, 
percentage of subjects with heart failure and duration 
of treatment.
For ACE inhibitor treatment begun within 48 hours of 
myocardial infarction, the pooled odds ratio for death 
(any cause) was 0.94 (95% Cl:0.90-0.98), and for 
treatment begun after this time but within 16 days, the 
pooled odds ratio was 0.75 (95% Cl:0.66-0.84) .
If 25% of the subjects treated with ACE inhibitors after 
infarction had heart failure, the odds ratio for all­
cause mortality was 0.84 (95% Cl: 0.77-0.91; however, if 
75% of the subjects had heart failure, then the odds 
ratio was 0.70 (95% Cl: 0.57-0.85) which implies that 
subjects with heart failure derive greater benefit from 
ACE inhibitor treatment after myocardial infarction.
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It was also found that the longer the duration of 
treatment, the greater the survival benefit as a result 
of ACE inhibitor treatment after myocardial infarction. 
The odds ratio for all-cause deaths was 0.92 (95% Cl: 
0.88-0.95) for one month's treatment, whereas it was 
0.79 (95% Cl: 0.72-0.87) for 12 months' treatment.
Age, sex and duration of follow-up did not appear to 
influence the odds ratio for all-cause mortality.
Data on cardiovascular deaths was provided for only four 
trials; thus, there was insufficient information to draw 
any conclusions in regard to the pooled odds ratio for 
cardiovascular deaths.
1.6 Summary of Findings
ACE inhibitors significantly improve survival after 
myocardial infarction. The benefits are greater if there 
is some degree of heart failure after infarction and if 
treatment is not begun until at least 24 hours after the 
infarction. The benefits are also greater the longer the 
duration of ACE inhibitor treatment.
The value of the mixed model method employed here in 
meta analysis is to identify sources of heterogeneity in 
outcomes amongst trials as a prelude to sub-group 
analysis. The method provides an expeditious means of 
identifying trends and providing policy and research 
directions without the need to resort to individual 
patient data from trialists. However, sub-group analysis 
using individual patient data is also needed for the 
proper development of clinical practice guidelines.
V1.7 Future Directions
Future directions include the confirmation of the 
effects of advanced age, baseline heart failure and 
duration of treatment by sub-group analysis, the 
examination of other endpoints, in particular reduction 
in the incidence of congestive cardiac failure and re­
infarction, to gain some insight into the reasons for 
the survival benefits of ACE inhibitors, and examination 
of other covariates such as dose and type of ACE 
inhibitor, whether short-acting or long-acting.
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Part A: The Technique of Meta Analysis
1. What is Meta Analysis?
1.1 Definition
Meta analysis is a technique for quantitatively 
combining the results of clinical trials. The method has 
been proposed to overcome the subjective nature of 
traditional reviews (1). In analysing clinical trials 
the difference between treated and control groups in the 
effect measure is determined. If this difference differs 
only randomly from zero it is very likely that the 
intervention has done nothing. In meta analysis the 
total of the differences between treated and control 
groups for several clinical trials is obtained. If this 
total difference also only randomly differs from zero it 
is likely that the intervention has done nothing. This 
is the basic principle of meta analysis.
Odds Ratio
For dichotomous outcome data which are the subject of 
the analysis in Part B, the result of a meta analysis is 
usually expressed as an odds ratio which is 
computationally easier to obtain than a relative risk. 
The assumption is then made that the odds ratio is 
approximately equal to the relative risk. This 
assumption holds true only if the baseline risk is low. 
If the baseline risk is high, then for treatments 
showing benefit (relative risk and odds ratio less than 
one), the relative risk is greater than the odds ratio; 
thus, the odds ratio underestimates the relative risk 
(and overestimates the strength of association).
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1.2 Uses
Meta analysis is being used to justify new research (in 
grant applications), develop clinical guidelines and 
assist health policy and the development of health 
services.
1.3 Important Steps
Important steps in a meta analysis are the 
identification of all relevant trials and the 
abstraction of the relevant data from them. There is a 
tendency to publish only interesting, usually positive, 
results ("publication bias"). Thus, clinical trial 
registers, institutional ethics committees' records and 
other sources need to be searched to find the 
uninteresting trials, arid uninteresting results. 
Identification of relevant studies is becoming easier 
with the development of clinical trial registers. 
However, the sharing of data needs to be encouraged 
since, even if relevant trial reports can be found, they 
often do not contain all the information needed for a 
meta analysis and trial investigators are often 
reluctant to provide the information.
Studies entered in a meta analysis must be sufficiently 
similar in design, population, intervention and outcome 
measures to allow meaningful interpretation of the 
combined result (1). Advances in diagnostic and 
therapeutic methods should be considered if the trials 
being pooled were done in different eras (2).
1.4 When Most Appropriate
Meta analysis is most appropriate when a particular 
intervention is of moderate rather than dramatic benefit 
but nevertheless the intervention has public health
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importance. When the benefit is moderate individual 
studies typically point in a favourable direction; 
however, they do not reach statistical significance.
1.5 Avoidance of Bias
Since in meta analysis moderate effects are being 
investigated rather than dramatic effects, bias may have 
a large impact on the result (3). Bias can occur at two 
levels: trial level and meta analysis level.
Randomisation, avoidance of exclusions after trial entry 
and blinding are important factors in overcoming bias at 
the trial level. Schulz et al (4) found, in a study of 
the Cochrane Pregnancy and Childbirth Database, that 
trials with inadequate concealment of treatment 
allocation and trials that were not double-blind 
exaggerated odds ratios in favour of treatment effect by 
41% and 17% respectively. Mengersen et al (5) showed, in 
a meta analysis of cohort and case-control studies of 
passive smoking and lung cancer, that bias may change 
estimates of differences in risk between treatment and 
control groups by as much as 50%.
At trial level, selection and measurement biases can be 
avoided by including, in the meta analysis, only 
randomised controlled trials with double-blinding and 
objective outcome measures. Intention-to-treat analysis, 
which includes all patients randomised, overcomes bias 
due to deliberately omitting subjects with poor 
compliance. Misclassification bias (with respect to 
diagnosis and covariates) is avoided with robust 
diagnostic methods; however, if such bias occurs in 
randomised trials, it would be expected to be equal in 
the treatment and placebo groups.
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At meta analyst level, selection bias is avoided by a 
thorough search for all the relevant trials, and the use 
of at least two people independently to decide which 
trials should be included in the analysis, and to 
extract the relevant data from each trial. Measurement 
bias is avoided by sound pooling methods, explanation of 
heterogeneity between trials and the use of sensitivity 
analysis.
1.6 How to Combine Information
Results can be combined using either fixed or random 
effects methods. An important consideration is why 
trials differ in their results. There are three reasons:
(a) sampling error within each trial
(b) random variation between trials, and
(c) trial characteristics (covariates).
The method used to combine trials should account for 
each of these sources of variation. A fixed-effects 
method without covariates such as the Peto Method (6) 
only accounts for (a); a random-effects method without 
covariates such as the DerSimonian and Laird Method (7) 
accounts for (a) and (b); whilst a random-effects method 
with covariates (regression) accounts for (a),(b) and 
(c) .
In the fixed-effects methods inference is conditional on 
the studies actually done, and all trials in the meta 
analysis are assumed to be estimating the same true 
effect of a fixed intervention, for example, ACE 
inhibitor treatment (8). Effect size estimates differ 
only as a result of sampling variability (within-trial 
variation). Between-trial variation is assumed to be 
zero, and only within-trial variation is used to obtain 
standard errors and 95% confidence intervals.
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In the random-effects methods inference is based on the 
assumption that the studies are a random sample from a 
hypothetical population of studies (8), and that each 
trial is estimating a different effect (related to 
differences between trials in subjects, methods and 
outcome measures). Effect size estimates differ as a 
result of both sampling variability within trials and 
variability between trials. The standard errors and 95% 
confidence intervals reflect both within-trial and 
between-trial differences.
When between-trial variation is minimal the fixed- and 
random-effects methods produce similar results. However, 
when there is significant between-trial variation 
(heterogeneity), the standard errors are greater and 
hence the confidence intervals for the effect estimates 
are wider for random-effects methods compared with 
fixed-effects methods. The random-effects methods give 
more realistic results if there is between-trial 
variation.
Peto Method
The Peto Method, which is widely used in practice, is a 
fixed-effects method. The pooled odds ratio (OR) is 
estimated as
In OR = E (0l-E1) /EV,
with standard error, se (In OR) = l/sqrtfEvj 
where
Oi = Observed number of deaths in the ACE inhibitor group 
in the ith trial
Ei = Expected number of deaths in the ACE inhibitor group 
in the ith trial if there were no treatment effect, and 
Vi = Variance of the difference (Oi-EJ .
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Heterogeneity of effect between trials is tested by a 
chi-square test on the statistic
Q = E { (Oj-EJ 7vj - E (O^-EJ
This tests the hypothesis that the degree of 
heterogeneity is no greater than that due to random 
variation.
DerSimonian and Laird Method
The DerSimonian and Laird Method, also widely used, is a 
random-effects method. The pooled odds ratio (OR) is 
estimated as
In OR = E (WilnORJ /EwL
with standard error, se (In OR) = l/sqrt(Ewi), where
ORt = Odds Ratio for the ith trial
= 1/(within-study variance+between-study variance).
Both the Peto and the DerSimonian and Laird methods are 
supported by the Cochrane Collaboration, an 
international consortium promoting and supporting meta 
analyses of randomised controlled trials in medicine.
Regression
The conventional meta analysis techniques have been 
criticised because they average the outcomes of the 
trials included (9,10). Even if the average differs from 
zero, trial results could be either favourable, 
indifferent or unfavourable. Averaging may be 
satisfactory if the trials are homogeneous; however, it 
can mislead when there is significant between-trial
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heterogeneity.
An important issue is why heterogeneity has occurred. 
Heterogeneous results amongst trials may relate to 
several factors, for example, differences in trial 
populations or treatment regimes and differences in the 
quality of the studies. These factors are referred to as 
explanatory variables or covariates. Some important 
covariates are age, sex, diagnosis, stage of disease, 
dose, timing and duration of treatment, and 
randomisation and blinding technique.
The use of regression enables covariates relating to 
each trial to be studied as a means of identifying 
causes of heterogeneity. Traditionally regression has 
been applied with all variables as fixed effects. Recent 
developments in statistics have allowed study of mixed 
models, which contain both fixed and random effects. 
Covariates relating to the trials are entered as fixed 
effects, and trial is entered as a random effect. The 
extent of heterogeneity amongst trials is determined by 
the trial variable.
Regression models can handle continuous, ordered and 
polytomous outcome variables as well as odds ratios from 
dichotomous outcome data. For example, person-time 
incidence rates could be studied (11).
Regression uses maximum likelihood to estimate effects. 
The effect estimates obtained are similar to the other 
methods if there is no adjustment for covariates.
A random-effects regression is presented in Part B of 
this sub-thesis.
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Bayesian Meta Analysis
The methods so far discussed adopt the frequentist 
approach of statistical inference which tests the 
hypothesis that there is a difference between treatment 
and control groups with a specified level of certainty 
(usually 95%). The Bayesian approach, rather than 
testing a hypothesis that one treatment is superior, 
directly estimates the treatment effect by combining 
prior knowledge with the current trial results (12).
DuMouchel (13,14) has developed the Bayesian method to 
incorporate a random trial effect, in what he calls a 
hierarchical Bayes linear model. There are two levels of 
variation in the model, the within-trial variation and 
the between-trial variation: Thus, the model has a 
similar structure to a mixed regression model. Prior 
distributions of the covariate coefficients and the 
between-trial variation are used in estimating treatment 
effects. The model can account for uncertainty in the 
between-trial variability, unlike the frequentist 
regression approach. An important issue is what to 
choose for the prior distributions. The practical use of 
the method is limited by the absence of reliable prior 
information on treatment effects (15).
1.7 Sub-Group Analysis
Regression is simply an efficient technique for looking 
at sub-groups. Hence, as in any sub-group analysis, some 
caution is needed. The numbers of patients and events in 
each group may be low; thus, effects due to chance may 
come out as significant. If too many sub-groups are 
analysed the chance of obtaining a significant result in 
any one analysis is increased.
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Specification of sub-group analyses a priori reduces the 
risk of being misled by a significant sub-group analysis 
result. In any case the use of sub-group analysis should 
be regarded as exploratory rather than confirmatory 
(16) .
2. Three Significant Meta Analyses
The technique of meta analysis has been applied to 
medicine for about 15 years. Three significant analyses 
which demonstrate the development of the technique are:
(a) Yusuf, S et al (17) - Beta Blockers During and After 
Myocardial Infarction (1985)
(b) AntiPlatelet Trialists' Collaboration (ATC) (18) - 
Secondary Prevention of Vascular Disease by Prolonged 
AntiPlatelet Treatment (1988) , and
(c) Law, MR et al (19,20) - Serum Cholesterol Reduction 
and Ischaemic Heart Disease (1994).
There are parallels between these studies and the meta 
analysis I will present in Part B.
2.1 Randomised Controlled Trials
The three meta analyses pool randomised controlled 
trials as I have done. The Law study also pools cohort 
studies; however, the pooling of cohort studies is 
outside the scope of this review. In this review the 
emphasis has been placed on randomised controlled trials 
so that the quality of trials does not become a 
significant issue.
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The three analyses were ideal candidates for meta 
analysis. They examine an intervention which is of only 
moderate benefit, but still of public health 
significance. Individual studies were favourable but did 
not achieve statistical significance, in respect of the 
intervention.
2.2 Intention-To-Treat Analysis
Intention-to-treat analyses were used. This type of 
analysis reduces the risk of bias due to differential 
withdrawal rates in the treatment and control groups. My 
meta analysis also uses intention-to-treat analysis.
2.3 Search Strategy
An appropriate search strategy to obtain all the 
relevant studies for the meta analysis was given for the 
Yusuf and ATC studies but not for the Law study. The 
strategy included use of literature data bases and 
reference lists of papers retrieved, and inquiry of 
colleagues. I have adopted the same approach in my 
study.
2.4 Pooling Technique
Yusuf and the ATC pooled studies using the Peto method 
whereas the Law study used fixed-effect logistic 
regression. The regression gave the same result as the 
Peto method when trials were weighted by size (21). 
However, the significance of the regression approach was 
that it identified mean change in total serum 
cholesterol from baseline as a factor in explaining the 
heterogeneity amongst trials. Law et al found that the 
best model weighted trials by the mean difference in 
total serum cholesterol concentration between treated 
and control groups.
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I used regression in my analysis to identify causes of 
heterogeneity.
2.5 Mortality As Effect Measure
All studies used mortality as one of the effect measures 
as I have in my meta analysis.
Yusuf obtained the mortality for two follow-up periods: 
less than or equal to one week, and greater than one 
week after beginning treatment. Law obtained the 
incidence of ischaemic heart disease events but not 
mortality for three follow-up periods: less than or 
equal to 2 years, 2.1 to 5 years, and 5.1 -12 years 
after beginning treatment. Time since randomisation for 
the Law meta analysis was also used as an explanatory 
variable in the logistic regression. This analysis 
demonstrated increasing benefit with increasing time 
since randomisation (21). The ATC study combined trials 
with follow-up periods from three months to six years 
but did not account for the different risks resulting 
from the different follow-up periods. This may lead to 
bias in estimates of effects.
In my analysis I have included follow-up time as a 
covariate.
2.6 Pooling of Total Mortality
The overall results based on total mortality for each 
meta analysis are given in Table 1.
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TABLE 1. POOLING OF THE ODDS RATIOS OF TOTAL MORTALITY 
FOR EACH META ANALYSIS
Meta
Analysis
Subjects
Randomised
Pooled Odds 
Ratio (95% Cl)
Heterogeneity 
of Effects
Yusuf et al
1 week oral 3, 611 0.93
(0.74-1.18)
not significant
1 week iv 
then oral
11,309 0.94
(0.76-1.14)
I » I »
> 1 week 20,312 0.77
(0.70-0.85)
if  I?
ATC
29,073 0.85 (vase)1 
(0.77-0.93)
not significant
29,073 0.93 (non-vase)1 
(0.78-1.13)
i i  ii
4
Law et al2
46,254 0.96
(0.90-1.02)
significant
Table 1 Notes
1. Results are for vascular and non-vascular mortality; 
total mortality was not provided.
2. In the Law meta analysis the pooled odds ratios are 
per 0.6 mmol/L reduction in serum cholesterol 
concentration.
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Significant features of these results are:
* Yusuf et al study: the odds of death were 
significantly reduced in the beta blocker group for 
periods of treatment greater than one week, but not for 
shorter periods.
* ATC study: the odds of cardiovascular death, but not 
non-cardiovascular death, were significantly reduced in 
the antiplatelet group. This result implies that 
antiplatelet treatment also reduced total mortality; 
however, this question could not be answered directly 
from the data in the report.
* Law et al study: the odds of death were not 
significantly reduced by reduction in serum cholesterol 
concentration. However, the odds of cardiovascular death 
were significantly reduced in the group receiving 
cholesterol-lowering treatment (odds ratio 0.90, 95% 
confidence interval 0.84-0.97). The authors believed 
that there were too few deaths from causes other than 
cardiovascular disease and that the follow-up period was 
insufficient (mean 4.6 years) to achieve a significant 
result for total mortality.
* Heterogeneity of effect on the mortality endpoint was 
not a problem for the Yusuf and ATC analyses but was a 
problem in the Law analysis. Heterogeneity for the Law 
study became non-significant when adjustments were made 
using logistic regression for the average extent of 
cholesterol reduction achieved and the duration of 
treatment.
Heterogeneity of effects was also a problem with my 
study.
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2.7 Sub-Group Analysis
Sub-group analysis was done in each meta analysis.
The Yusuf study examined beta-blockers with and without 
intrinsic sympathomimetic activity (ISA) obtaining a 
significant reduction in the odds of death in the group 
treated with non-ISA beta-blockers but not in the group 
treated with ISA beta-blockers. This result has been 
challenged as being possibly due to chance, and has not 
influenced treatment guidelines at the present time.
The ATC study examined the type of antiplatelet 
treatment used (high- and medium-dose aspirin, aspirin 
plus dipyridamole, and sulphinpyrazone) and found that 
all types of antiplatelet treatment, when compared with 
placebo, produced significant reductions in the odds of 
death; however, when the treatments were compared with 
each other there was no difference in the odds of death. 
The authors argued that the numbers randomised were 
insufficient to achieve significant results for the 
active treatment comparisons: there were 703 subjects 
randomised for the aspirin-sulphinpyrazone comparison, 
and 3,194 for the aspirin-aspirin+dipyridamole 
comparison.
The Law study examined the sub-groups, drug treatment 
and dietary treatment, and the sub-groups, ischaemic 
heart disease and no ischaemic heart disease at 
baseline. There were no differences in the odds of death 
from any cause between drug and diet treatment; however, 
the odds of non-cardiovascular death were increased 
compared with placebo in those receiving drug therapy to 
lower serum cholesterol (odds ratio 1.20, 95% confidence 
interval 1.02-1.40). The odds of death from any cause 
were reduced compared with placebo in subjects with 
ischaemic heart disease at baseline (odds ratio 0.90,
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95% confidence interval 0.^84-0.97).
These results, even though they have been obtained by 
sub-group analysis a posteriori have influenced 
treatment guidelines. There is an awareness amongst 
prescribers of a possible increase in non-cardiovascular 
deaths from cholesterol-lowering therapy with drugs, and 
cholesterol-lowering therapy is specifically directed at 
those patients with existing ischaemic heart disease 
(secondary prevention).
In my meta analysis regression was used to predict 
effects in sub-groups.
2.8 Policy Implications
All studies have had a significant impact on clinical 
practice. The Yusuf and ATC results which were not 
marred by the problem of heterogeneity of effects have 
been almost universally accepted.
Law et al argue for'serum cholesterol-lowering in both 
primary and secondary prevention of ischaemic heart 
disease. The Law data do not support the primary 
prevention indication since a non-significant difference 
in the odds of death between treatment and control 
groups was obtained (odds ratio 1.06, 95% confidence 
interval 0.97-1.17).
Whilst serum cholesterol-lowering for secondary 
prevention has been generally accepted, serum 
cholesterol-lowering for primary prevention has not, 
some meta analyses (including Law's) supporting it and 
others not supporting it. Silberberg (22) argues that 
these different interpretations arise from selective 
inclusion of trials and choice of trial weights for the 
meta analysis. This illustrates a danger of meta
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analysis. The Law meta analysis appears to be the most 
rigorous since it weights trials on the extent of serum 
cholesterol reduction and considers the duration of 
treatment.
2.9 Implications For My Study
I have considered the techniques in these three meta 
analyses and applied them to the meta analysis in Part B 
of this review.
I have restricted my meta analysis to randomised 
controlled trials to reduce bias due to selection and 
confounding, I have applied intention-to-treat analysis 
to overcome bias from the deliberate omission of 
subjects with poor compliance, and I have used mortality 
as the effect measure because it is easy to assess and 
is a clinically-relevant endpoint.
I have adopted a similar three-stage search strategy of 
use of the literature databases, thence use of the 
reference lists of papers retrieved, and finally enquiry 
of colleagues.
For pooling trials I used a new technique of mixed 
models, a random effects approach which can incorporate 
several covariates. This technique allows sub-groups to 
be examined efficiently, and reasons for heterogeneity 
of effects to be identified. A priori hypotheses were 
made with respect to the covariates of interest.
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Part B: Application to the Use of ACE 
Inhibitors in Myocardial Infarction
1. Introduction
1.1 Development of Heart Failure After Myocardial 
Infarction
After a myocardial infarction the sympathetic nervous 
system and the renin-angiotensin system become 
activated. The activation of these systems is maximal 
within the first 72 hours and has resolved by 7-10 days 
(23,24). Plasma levels of noradrenaline and angiotensin 
II become elevated. The activation is greatest in 
patients with left ventricular dysfunction (24). These 
hormones increase systemic vascular resistance and 
consequently left ventricular pre-load and after-load. 
Greater stress is placed on the left ventricular wall 
causing thinning and elongation of the infarcted area. 
Meanwhile, the remaining viable myocardium hypertropies 
to compensate for the lost myocardium. Thus, a process 
of left ventricular remodelling ensues. This process 
begins within two weeks of infarction and may continue 
for six months (25,26).
Remodelling reduces myocardial function and 
progressively leads to congestive cardiac failure in 
approximately 20% of patients after myocardial 
infarction (26). The underlying ischaemia contributes to 
the diminution in cardiac function by a vicious cycle 
where diminished cardiac function leads to further 
ischaemia.
Congestive cardiac failure has a poor prognosis. This 
was clearly demonstrated in early studies (27,28), and 
confirmed in a study by Stevenson et al (29) since the
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introduction of thrombolysis. In this study the 
mortality rate at three years in patients with 
congestive cardiac failure following myocardial 
infarction was 55.4% compared with 17.4% in those 
without congestive cardiac failure.
1.2 ACE Inhibitors After Myocardial Infarction
Angiotensin-converting enzyme (ACE) inhibitors are 
potent vasodilators. It was hypothesised that ACE 
inhibitors would limit ventricular enlargement after 
myocardial infarction by reducing afterload (30-2) . 
Clinical trials have been designed to test, firstly, 
whether ACE inhibitors limited ventricular enlargement 
post-myocardial infarction, and secondly, whether they 
improved survival.
There have been several large randomised controlled 
trials of the survival benefit of ACE inhibitors after 
myocardial infarction. Some studies have demonstrated a 
benefit (25,33,34,35) whilst others (36) have not. Key 
issues appear to be'the time of commencement of the ACE 
inhibitor after infarction, the initial dose and route 
of administration, and the degree of left ventricular 
dysfunction.
Beneficial Effects
Several mechanisms of action have been proposed for the 
beneficial effects of ACE inhibitors after myocardial 
infarction.
Firstly, ACE inhibitors inhibit the activation of the 
sympathetic nervous system and the renin-angiotensin 
system (33,36,37). As a consequence, plasma levels of 
noradrenaline and angiotensin II are reduced and less 
stress is placed on the left ventricular wall. The left
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ventricular remodelling process is thereby attenuated, 
improving cardiac output and reducing the development of 
congestive cardiac failure (33,35,38).
Secondly, ACE inhibitors have an anti-ischaemic effect 
by virtue of their vasodilatory action. Coronary blood 
flow is thereby increased, and there is less risk of the 
infarcted area expanding; thus, attenuating left 
ventricular remodelling and breaking the vicious cycle 
of ischaemia causing diminished cardiac function which 
in turn causes more ischaemia. This effect is supported 
by the SAVE (33), SOLVD (39,40) and AIRE (35) studies 
which demonstrated a reduced recurrence rate of 
myocardial infarction in patients treated with ACE 
inhibitors.
Thirdly, ACE inhibitors exert an anti-arrhythmic effect. 
This proposal is supported by the reduced incidence of 
ventricular arrhythmias in subjects treated with the ACE 
inhibitor, zofenopril, compared with those treated with 
placebo in the SMILE pilot study (41). The anti- 
arrhythmic effect may be due to better myocardial 
perfusion as a result of vasodilation induced by the ACE 
inhibitor.
Finally, ACE inhibitors may prevent atherosclerotic 
plaque formation, plaque rupture and thrombosis after 
plaque rupture. Angiotensin II stimulates platelet- 
derived growth factor and the migration of neutrophils 
and macrophages into blood vessel walls, and is also 
believed to increase lipid uptake into vessel walls 
(42). These processes lead to atherosclerosis, and may 
be curbed by an ACE inhibitor. Stimulation of the renin- 
angiotensin system, because it increases vasomotor tone, 
has the potential to increase plaque rupture. This 
process could also be curbed with the use of an ACE 
inhibitor.
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Adverse Effects
On the other hand, there are two proposed mechanisms for 
the failure of ACE inhibitors to improve survival after 
myocardial infarction.
Firstly, ACE inhibitors reduce blood pressure and, 
hence, myocardial perfusion. The corresponding increased 
ischaemia increases the risk of infarct extension, and 
the risk of re-occlusion in situations where 
thrombolytic treatment has been used to re-open occluded 
coronary vessels (23) . The hypotensive effect will be 
more pronounced if a more potent or faster-acting ACE 
inhibitor is used, a larger initial dose is employed or 
the ACE inhibitor is given by the intravenous route.
Secondly, angiotensin II stimulates myocardial protein 
synthesis early after myocardial infarction, and this 
may be important in stimulating the healing process, in 
particular compensatory cardiac muscle cell 
proliferation (36). If this process is blocked by use of 
an ACE inhibitor, healing is thereby reduced. (It could 
be argued that blocking the healing process is a good 
thing, because healing may cause potentially damaging 
left ventricular remodelling).
Optimal Commencement Time
There appears to be an optimal time after infarction 
when the beneficial effects of ACE inhibition take over 
from the adverse effects. The SAVE study (33), which 
began ACE inhibitor treatment not earlier than three 
days after myocardial infarction, showed survival 
benefits; whereas the CONSENSUS II study (36), which 
began treatment within 24 hours of infarction, did not 
show survival benefits. Why?
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To achieve maximal inhibition of the renin-angiotensin 
system treatment must begin within 72 hours, and to have 
an impact on left ventricular remodelling ACE inhibitor 
treatment must begin within two weeks of an infarction 
(23,24). However, soon after infarction, the myocardium 
is sensitive to the hypotensive insult induced by ACE 
inhibitors. The duration of the sensitive period varies 
from case to case and could be as long as 48 hours. It 
may be possible to identify the sensitive period with 
the use of a small test dose of an ACE inhibitor. The 
optimal timing for stimulation of myocardial protein 
synthesis after infarction is unknown. Thus, there are 
several factors determining the optimal commencement 
time of ACE inhibitors after myocardial infarction.
Left Ventricular Dysfunction
Having determined an optimum time to begin ACE inhibitor 
treatment, there are other factors which are believed to 
influence the magnitude of any survival benefit. Greater 
survival benefits have been postulated if there is some 
evidence of left vehtricular dysfunction following 
infarction. The SAVE (33) and AIRE (35) studies 
demonstrated a greater survival benefit in subjects with 
left ventricular dysfunction; whereas the CONSENSUS II 
study (36), which did not specifically select subjects 
with left ventricular dysfunction, did not demonstrate 
survival benefits.
There is greater sympathetic and renin-angiotensin 
system activation in patients with left ventricular 
dysfunction compared with other patients, and, 
therefore, curbing the activity of these systems in such 
patients would be expected to have a greater impact 
(33,35).
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Ischaemia
Greater survival benefits from ACE inhibitors have also 
been postulated where thrombolysis has either failed or 
has not been used after infarction (35) . In such 
situations ischaemia persists longer than in other 
situations; thus, it is presumed that the anti-ischaemic 
effect of ACE inhibitors has a greater impact.
Optimum Duration of Treatment
Another factor to be determined is the optimum duration 
of treatment with ACE inhibitor after myocardial 
infarction. There is evidence that, if the ACE inhibitor 
is used only in the first critical weeks after 
infarction when the events previously described are 
occurring, the survival benefits will persist for at 
least 12 months.
In the SMILE study (25), only six weeks treatment with 
an ACE inhibitor was given; however, the survival 
benefit of zofenopril over placebo was maintained at 12 
months of follow-up. The benefits of ACE inhibitor 
treatment in this study appear to derive from events 
occurring immediately after the infarction, in 
particular renin-angiotensin system activation and left 
ventricular remodelling.
On the other hand, the SAVE study with captopril did not 
demonstrate survival benefits until after 12 months' 
treatment, and the CONSENSUS II study with enalapril had 
not demonstrated any survival benefits at six months 
when it was terminated.
If ACE inhibitors have anti-ischaemic and anti-plaque 
effects then additional survival benefits could be 
expected from longer treatment.
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Questions
ACE inhibitor studies to date raise several questions:
* Should treatment be started as soon as possible after 
infarction or delayed for 24-48 hours?
* What is the optimum duration of treatment?
* What is the optimum treatment population?
* What is the optimum dose?
* Why do ACE inhibitors improve survival in some 
patients and not in others?
2. Objective
The objective of this review is to determine the 
survival benefit of ACE inhibitors when used early 
(within 16 days) after myocardial infarction, and to 
determine the optimum treatment regime, duration of 
treatment and treatment population. The outcomes of 
interest are cardiovascular deaths and total deaths.
Hypotheses
* ACE inhibitors diminish survival if started earlier 
than 24 hours after a myocardial infarction.
* ACE inhibitors have a greater impact on the survival 
of subjects with some degree of left ventricular 
dysfunction than no left ventricular dysfunction after 
myocardial infarction.
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* ACE inhibitors have a greater impact on survival after 
myocardial infarction if used in subjects under the age 
of 70 years than if used in subjects 70 years and over.
* ACE inhibitors after myocardial infarction have an 
equal impact on survival for males and females.
* A treatment duration of at least one month is needed 
for ACE inhibitors to improve survival after myocardial 
infarction.
3. Criteria for Considering Trials for This 
Review
Study Design
Randomised placebo-controlled trials.
Types of Participants
Patients within 16 days of a myocardial infarction.
Myocardial infarction is defined as typical symptoms 
with:
* ST elevation and/or T-wave inversion on 
electrocardiogram (ECG), or
* changes in Q waves on serial ECGs, or
* elevation of myocardial enzymes.
Intervention
ACE inhibitor.
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Outcome Measures
Cardiovascular mortality and total mortality.
4. Search Strategy for Identification of Trials
Published trials were identified by a systematic search 
of Medline, Embase, Current Contents, Biosis and 
Scisearch.
4.1 Medline
The Medline search provided the majority of the trials 
identified. The Medline search strategy was as follows:
(a) thesaurus "ACE inhibitors" (exploded)
(b) thesaurus "myocardial infarction" (exploded)
(c) "human in tg"
. (d) "not review" (1966-93)
(e) "clinical-trial in pt".
A browse was done at point (d) and an additional 
clinical trial not tagged as such was identified 
(Mourao,L et al). The search was broad-based for 1994- 
95, retrieving not only clinical trial reports but also 
other articles including reviews and letters. The other 
articles were examined to identify any other relevant 
clinical trials. The bibliographies of the clinical 
trial reports were examined to identify other studies. 
Animal studies were excluded from the search.
4.2 Embase
Embase was searched on "ACE inhibitors" and "myocardial 
infarction" for the period 1989 to May 1994; resulting 
in one additional trial being identified (a study by Di 
Pasquale et al not amongst the Di Pasquale studies found
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on Medline); however, this trial did not meet the 
inclusion criteria since it was not placebo-controlled.
4.3 Other Databases
The other databases were searched from January to June 
1995 to identify the more recent published studies. A 
preliminary report of the TRACE study was found on 
Medline; however, the final results of this study were 
obtained from the Dialog search. Current Contents 
identified the SMILE and CCS trials. Biosis and 
Scisearch did not provide any new information. The 
search results are given in Tables 1 and 2.
TABLE 1. ACE INHIBITORS WITHIN 16 DAYS OF MYOCARDIAL 
INFARCTION: TRIALS IDENTIFIED FROM MEDLINE "CLINICAL- 
TRIAL" SEARCH
Source Items Trials Incl or 
Excl
Reason for 
Excl
Medline 1/94- '41 Flather,M: Incl
1/95 ISIS-4 Pilot
Bonaduce,D Excl No data on
et al mortality
Sogaard,P et Excl T T
al: 3 papers
Wright,RA et Excl T !
al
Tohmo,H et Excl f 1
al
Santos,JM et Excl I 1
al
Foy,SG et Incl
al:PRACTICAL
Mareev,VIU Excl Not placebo
et al controlled
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TABLE 1 (CONT). TRIALS IDENTIFIED FROM MEDLINE 
"CLINICAL-TRIAL" SEARCH
Source Items Trials Incl or 
Excl
Reason for 
Excl
Medline 1/94- Donald,RA et Excl No data on
1/95 (cont) al mortality
Kettunen,RV Excl i i
et al
GISSI-3 Incl
Di Pasquale, Excl No data on
P et al mortality
TRACE Incl
Kyriakidis,M Excl No data on
K et al mortality
•
CADS Excl V f
ECCE Excl I I
Kingma,JH et Excl I f
al: CATS
Omland,T et Excl i i
al
Lu,CY et al Incl
Medline 1990-93 55 Sigurdsson,A Excl No data on
2 papers mortality
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TABLE 1 (CONT). TRIALS IDENTIFIED FROM MEDLINE 
"CLINICAL-TRIAL" SEARCH
Source Items Trials Incl or Reason for
Excl Excl
Medline 1990-93 AIRE Incl
(cont)
Jansson,JH Excl No data on
et al mortality
Motwani,JG Excl i i
et al
Gonzalez- Excl i i
Fernandez,RA 
Sogaard,P et 
al
Excl f f
Ray,SG et al Excl f f
Galcera- Excl f i
Tomas,J 
Pipilis,A et Excl i  I
al 2 papers 
Tranchesi- Excl f I
Junior,B 
Borghi,C et 
al
Excl I f
Kleber,FX et Excl I ?
al Di
Pasquale,P Excl V V
et al
Villalpando- 
Gutierrez,J
Excl ? f
Frost,L et Excl I  I
al
Hargreaves,A 
D et al
Excl 1 1
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TABLE 1 (CONT). TRIALS IDENTIFIED FROM MEDLINE 
"CLINICAL-TRIAL” SEARCH
Source Items Trials Incl or 
Excl
Reason for 
Excl
Medline 1990-93 SAVE Incl
(cont)
Bonaduce,D: Excl Mortality
2 papers not endpt
CONSENSUS II Incl
Gotzsche,CO Excl Mortality
et al not endpt
Bussmann,WD Excl i ?
et al
Nabel,EG et Excl ? ?
al
Pinzur,SV et Excl f f
al
Ambrosioni,E Incl
et al
Oldroyd,KG Excl Mortality
et al not endpt
Sharpe,N et Excl i i
al: 2 papers
Di Pasquale, Excl ? T
P et al
Medline 1989 3 Nil
Medline 1982-88 3 Pfeffer,MA Excl Mortality
et al not endpt
Sharpe,N et Excl
al
Medline 1966-81 3 Brivet,F et Excl Mortality
al not endpt
TABLE 2. ACE INHIBITORS WITHIN 16 DAYS OF MYOCARDIAL 
INFARCTION: TRIALS IDENTIFIED FROM OTHER SOURCES (NOT 
FOUND ON MEDLINE "CLINICAL-TRIAL" SEARCH)
Source Trials Incl
or
Excl
Reason for 
Excl
Broad Medline Mourao,L et Excl No data on
search (not al mortality
restricted to
"clinical-trial
in pt"
Bibliography of ISIS-4 Incl
articles
identified by Hochman,JS et Excl Incomplete
Medline and a l :CAPTIN
supplementary Jugdutt,B et Excl No data on
Medline search al mortality
to 5/95 Latini,R: Incl
GISSI-3 Pilot
Sigurdsson,A Excl No data on
et al mortality
Embase 1989-5/95 Di Pasquale, Excl No placebo
P et al control
Current Contents Ambrosini,E Incl
1/95-6/95 et al:SMILE
CCS Incl
Dialog TRACE:final Incl
results
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Legend (Tables 1 and 2) :
CADS Captopril and Digoxin Study
CATS Captopril and Thrombolysis Study
CCS Chinese Cardiac Study
ECCE Effects of Captopril on Cardiopulmonary
Exercise Parameters
GISSI-3 Gruppo Italian© per lo Studio della
Sopravvivenza nell'Infarto Miocardico 
ISIS-4 Fourth International Study of Infarct Survival 
PRACTICAL Placebo-Controlled Randomised ACE Inhibitor
Comparative Trial in Cardiac Infarction and LV 
Function
SMILE Survival of Myocardial Infarction Long-Term
Evaluation
TRACE Trandolapril Cardiac Evaluation Study
4.4 Unpublished Trials
An attempt to identify unpublished trials was made by 
discussions with colleagues. No unpublished trials were 
found.
5. Trials Selected For Meta Analysis
5.1 Trials
Fourteen trials were identified as satisfying the search 
criteria (Section 3). The trials were:
SAVE (33)
CONSENSUS II (36)
GISSI-3 Pilot (43)
GISSI-3 (34)
Lu,CY et al (44)
PRACTICAL (38)
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SMILE Pilot (41)
SMILE (25)
ISIS-4 Pilot Phase 1 (23)
ISIS-4 Pilot Phase 2/3 (23)
ISIS-4 (37,45-47)
AIRE (35)
CCS (6)
TRACE (48,49).
5.2 Likelihood of Missed Trials
A funnel plot was used to determine the likelihood that 
relevant trials were missed due, for example, to 
publication bias. The number of subjects (a measure of 
precision) versus the odds ratio for each of the 14 
included published trials was plotted (Figure 1). 
Assuming all trials are estimating the same value of 
effect (fixed effect), the spread of results would be 
expected to narrow as the precision (number of subjects) 
increases (11). Thus, if there are no missing trials, 
the plot should form the shape of an inverted funnel.
A favourable meta analysis of several small magnesium 
trials was recently refuted by a large trial (ISIS-4, a 
factorial trial involving treatment with both captopril 
and intravenous magnesium). Egger and Davey Smith (50) 
argued that the meta analysis was affected by 
publication bias, negative studies not being published, 
and this was shown by a gap in the funnel plot.
- 33-
60000
N o - 50000 
Subjects 40000
30000
20000
10000
0
0.00 0.50 1.00 1.50 2.00
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Figure 1. Funnel Plot of Included Trials
Figure 1 is sparse because there were only 14 points; 
thus, there are dangers in using it for pattern 
recognition (51). The assumption of fixed effects for 
this data is also contentious. Nevertheless, an inverted 
funnel shape can be made out and this provides a rough 
guide that the trials selected represent most of the 
relevant trials. There possibly should be more small 
negative (odds ratio greater than one) trials.
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5.3 Data Extracted
The included trials enrolled 107,005 subjects. The 
trials met the diagnostic criteria for myocardial 
infarction as stated in Section 3. Since only randomised 
trials have been considered, any misclassification with 
respect to the diagnosis of myocardial infarction would 
be expected to be equal in the ACE inhibitor and placebo 
groups. The inclusion of patients without infarction, 
assuming they have a better prognosis, would 
underestimate any survival benefit in the ACE inhibitor 
group.
The data extracted from the trials is given in Appendix
I, and descriptions of the trials are given in Appendix
II.
The number of subjects with each outcome event was 
extracted, by allocated treatment group, irrespective of 
compliance, and whether or not the subject was 
subsequently excluded from treatment or follow-up, so as 
to allow an intention-to-treat analysis. Data on 
covariates sufficient to test my a priori hypotheses was 
collected.
6. Methods of Analysis
6.1 Outcomes of Interest
The outcomes of interest were total mortality and 
cardiovascular mortality.
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6.2 Analysis of Individual Trials
The Cochrane Collaboration software Revman (52) was used 
to calculate the odds ratios and their 95% confidence 
intervals for the individual trials.
6.3 Combined Analysis
The data from the individual trials was combined using 
generalised linear mixed models.
Binomial response variables, the proportion of deaths 
(any cause) and the proportion of deaths (cardiovascular 
causes) in the ACE inhibitor and placebo groups, were 
used to estimate the probability of death (all causes) 
and the probability of death (cardiovascular causes).
The response variables were fitted with a logit link 
(logistic regression). The corresponding odds ratios 
were then calculated from the estimates of the odds of 
death (all-causes and cardiovascular causes) in the ACE 
inhibitor and placebo groups.
The responses, probability of death (all causes) and 
probability of death (cardiovascular causes), can vary 
at two levels, the within-trial level and the between- 
trial level. Thus an appropriate statistical model will 
include random effects for between-trial and within- 
trial variability and fixed effects for the factors of 
interest (covariates) associated with the trials. This 
was the approach adopted.
The trial covariates were chosen so that my a priori 
hypotheses could be tested. The covariates were 
treatment, time of commencing treatment, age, proportion 
of subjects over age 70 years, sex, proportion of 
subjects with heart failure (Killip Class>l, or clinical 
heart failure), mean duration of treatment and mean
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duration of follow-up.
Since the covariates are at the trial level rather than 
the subject level and relate to trial outcomes rather 
than individual outcomes the a priori hypotheses can be 
tested only indirectly. The robustness of this approach 
is examined for the effects of sex and baseline heart 
failure by sub-group analyses in males, females and 
those with baseline heart failure.
The models had the following structure:
Probability of death (all-causes and cardiovascular 
causes)
= Constant
+ Effect due to ACE inhibitor treatment 
+ Effect due other covariate
+ Interaction Effect between treatment and other 
covariate
+ Random Between-Trial Error 
+ Random Within-Trial Error.
The method efficiently pools the between-trial and 
within-trial error; thus, more realistic standard errors 
are obtained, and inference is more accurate.
Some trials did not provide data for all covariates. 
Thus, I examined the impact of one covariate at a time 
on treatment, and included trial as a random effect.
The mean duration of treatment and the mean duration of 
follow-up data were skewed. Log transformations of these 
covariates were taken to overcome this problem.
The impact of quality of trials was tested by removing 
trials of potentially poorer quality and noting the 
effect on outcome.
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The models were computed with Genstat software (53), 
which uses the method of Schall (54). Diagnostic plots 
were done for each model to ascertain whether the model 
assumptions of constant variance and normality were met. 
The plots were of residuals versus fitted values, and 
residuals versus normal variates.
7. Analysis
7.1 Deaths - All Causes
7.11 Analysis of Individual Trials
The odds ratios and 95% confidence intervals for each 
trial are listed in Table 3, and plotted in figure 2.
The PRACTICAL trial which was a three-arm study 
involving captopril, enalapril and placebo groups was 
entered into Revman as two trials. The two trials are 
not independent since each trial has the same placebo 
group.
The 14 trials randomised a total of 107,005 subjects in 
whom there were 12,247 deaths. The largest trial, ISIS- 
4, accounted for 54.2% of the subjects.
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TABLE 3. ODDS RATIOS OF DEATH ANY CAUSE (ACE INHIBITOR 
VERSUS PLACEBO) OBTAINED USING KEVMAN
No Trial No Deaths/No 
Subjects
Odds
Ratio
95%
Confidence 
Interval of 
Odds RatioACEInhib
Placebo
1 SAVE 228/ 275/ 0.79 0.64-0.96
1115 1116
2 CONSENSUS II 312/ 286/ 1.10 0.93-1.30
3044 3046
3 GISSI-3 597/ 673/ 0.88 0.79-0.99
9435 9460
4 Lu et al 3/ 8/ 0.47 0.13-1.66
43 55
5 CCS 617/ 654/ 0.94 0.84-1.05
6814 6820
6 PRACTICAL 10/ 0.81 0.33-1.99
Captopril 75 12/
6 PRACTICAL 2/
75 0.21 0.07-0.63
Enalapril 75
7 SMILE Pilot 8/ 11/ 0.72 0.28-1.85
101 103
8 SMILE 77/ in/ 0.67 0.50-0.92
772 784
9 ISIS-4 3/ 5/ 0.60 0.15-2.46
Pilot 1 133 134
10 ISIS-4 21/ 14/ 1.54 0.77-3.06
Pilot 2/3 237 237
TABLE 3 (CONT) . ODDS RATIOS OF DEATH ANY CAUSE (ACE 
INHIBITOR VERSUS PLACEBO) OBTAINED USING FEVMAN
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No Trial No Deaths/No 
Subjects
Odds
Ratio
95%
Confidence 
Interval of 
Odds RatioACEInhib
Placebo
11 ISIS-4 3480/
29028
3636/
29022
0.95 0.91-1.00
12 AIRE 170/
1014
222/
992
0.70 0.56-0.87
13 GISSI-3
Pilot
41/
509
98/
1017
0.83 0.57-1.20
14 TRACE 307/
876
366/
873
0.75 0.62-0.91
POOLED 5876/
53271
6371/
53734
0.92 0.88-0.95
Between-trial test for heterogeneity; x2 (df=14) 34.68.
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for Included Trials
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ACE inhibitor treatment significantly (p<0.05) increased 
survival compared with placebo in 7 trials, and there 
was a non-significant result in 8 trials (the PRACTICAL 
trial being counted twice because of its three treatment 
arms). The individual odds ratios ranged from 0.21 to 
1.54. The trials with these extreme odds ratios were 
small. Of the three trials with more than 10,000 
subjects, two (GISSI-3, ISIS-4) were just significant 
and the other (CCS) non-significant. Thus, a clear 
judgement of the survival benefit or otherwise of ACE 
inhibitors after myocardial infarction cannot be made on 
the basis of individual analysis; however, there is a 
suggestion of moderate benefit which may have public 
health importance. Combined or meta analysis is 
appropriate.
7.12 Combined Analysis
ACE Inhibitor Treatment Unadjusted for Other Covariates
For deaths (all causes) the mixed model yielded a pooled 
odds ratio of 0.92 with 95% confidence interval 0.88- 
0.95. By way of comparison and as a means of validating 
the mixed model approach the pooled odds ratios were 
also obtained using the Peto Method and the DerSimonian 
and Laird Method. The computation was done using Revman 
for the Peto Method and Excel (55,56) for the 
DerSimonian and Laird Method. The results are given in 
Table 4.
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TABLE 4. POOLED ODDS RATIOS OF DEATH ALL CAUSES (ACE 
INHIBITOR VERSUS PLACEBO) BY THREE METHODS
Method Pooled Odds 
Ratio
95% Confidence 
Interval of 
Pooled Odds 
Ratio
Mixed Model 0.92 0.88-0.95
Peto Method 0.92 0.88-0.95
DerSimonian & Laird Method 0.86 0.79-0.94
The methods do not differ significantly since their 95% 
confidence intervals overlap; however, the DerSimonian 
and Laird Method produces a lower odds ratio and a wider 
confidence interval than the other methods. It is 
noteworthy that the fixed effect Peto Method yields a 
similar result to the mixed model without adjustment for 
covariates. This has occurred because there are equal 
numbers of controls and treatments at the trial level 
and no confounding between odds ratio and treatment; in 
other words, treatment is orthogonal to trial. However, 
this is not the case when other covariates are added to 
the model.
The pooled odds ratio indicates that ACE inhibitor 
treatment reduced deaths significantly compared with 
placebo treatment. However, the variance component 
associated with the trial term, which represents the 
between-trial heterogeneity, was significant (p~0.01).
It is necessary to add covariates to the model to reduce 
this heterogeneity before validly inferring benefit from 
ACE inhibitor treatment.
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Impact of Study Quality
Trials which may have been of doubtful quality were 
removed to assess their impact. There were six unblinded 
trials (GISSI-3 pilot, GISSI-3, SMILE pilot, ISIS-4 
pilots 1 and 2/3, and ISIS-4) and one trial (CCS) where 
blinding was not specified. The pilot studies were small 
with wide 95% confidence intervals for their estimates 
of treatment effect. All of these trials were considered 
lower quality because of sampling variability as well as 
open design. GISSI-3, ISIS-4 and CCS were very large 
trials; thus, their 95% confidence intervals for the 
estimates of treatment effect were narrower and there 
was less risk of their open designs producing biased 
results. But, the GISSI-3 trial also failed to account 
for exclusions from follow-up and did not have an 
intention-to-treat analysis, and the CCS trial provided 
limited information. Two other trials, Lu and TRACE, 
also provided limited information. These trials were 
also considered lower quality.
The trials removed were the pilot studies, GISSI-3, CCS, 
Lu and TRACE. The pooled odds ratio obtained was 0.93 
(0.89-0.97) which is not much different from .the overall 
analysis. Thus, the trials of potentially doubtful 
quality do not appear to have influenced the meta 
analysis. Heterogeneity between trials remained 
significant; thus, the quality of trials also does not 
explain the between-trial heterogeneity.
ACE Inhibitor Treatment Adjusted By Other Covariates
The model was adjusted by adding the covariates of 
interest and noting their significance and impact on the 
between-trial variability.
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The covariates of interest were as follows:
Time of Commencing Treatment (com)
0: <=48 hours after infarction 
1: > 48 hours after infarction
Mean Age (age)
Percentage of Subjects Aged 70 Years and Over (A70) 
Percentage of Subjects with Heart Failure (Hfail) 
Percentage of Subjects Who Were Male (%males)
Mean Duration of Treatment (DurT)
Mean Duration of Follow-Up (DurF).
Model 1 - Impact of Time of Commencing’ ACE Inhibitor 
Treatment (com*treat)
The effects of com, treat and the interaction com*treat 
were all significant (p<0.05). The addition of com and 
com*treat to the model reduced the variance component 
associated with the trial term so that it became non­
significant at the 5% level, suggesting that com and 
com*treat have explained some of the between-trial 
heterogeneity. The model for the pooled odds ratio (OR) 
was:
OR = exp(-0.06196-0.23020(com))
with standard errors 0.02054 for the constant and 
0.06342 for the coefficient of com.
The pooled odds ratios obtained from this model are 
given in Table 5, and a comparison for commencing ACE 
inhibitor within and beyond 48 hours of infarction is 
given in figure 3.
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TABLE 5. POOLED ODDS RATIOS OF DEATH ALL CAUSES (ACE 
INHIBITOR VERSUS PLACEBO) ADJUSTED FOR TIME OF 
COMMENCEMENT OF TREATMENT
Time of Commencing 
Treatment
Pooled Odds Ratio 95% Confidence 
Interval of 
Pooled Odds Ratio
<= 48 hours after 0.94 0.90-0.98
infarction
> 48 hours after 0.75 0.66-0.84
infarction
p<0.05
BeyondWithin
48 48
Hours Hours
Figure 3. Pooled Odds Ratios for Death (All 
Causes) for Trials Where ACE Inhibitor Treatment 
Was Begun Within and Beyond 48 Hours of 
Myocardial Infarction
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The effect of the time of commencing treatment on the 
pooled odds ratio is dramatic. The odds reduction for 
all-cause mortality as a result of ACE inhibitor 
treatment is 25% if the treatment is commenced greater 
than 48 hours after myocardial infarction compared with 
only 6% if treatment is commenced within 48 hours.
It is worth noting that, of the subjects who commenced 
ACE inhibitors within 48 hours of infarction, the 
majority (86%) commenced ACE inhibitors within 24 hours. 
Of those who commenced ACE inhibitors beyond 48 hours 
after infarction, the average time of commencement was 
approximately 6 days with a range of 3 to 16 days. Thus, 
the optimal time for commencement of ACE inhibitors 
appears to lie between one and six days. This result 
supports my first hypothesis that ACE inhibitors 
diminish survival benefit if started earlier than 24 
hours after a myocardial infarction.
An important factor not considered is that those trials 
which enrolled patients beyond 48 hours after infarction 
were treating patients who had survived the critical 
first days after infarction whereas those enrolling 
patients within 48 hours of infarction had a higher 
percentage of patients who died in the critical first 
days. To examine the impact of this factor individual 
patient data on the early deaths is needed.
Model 2 - Impact of Mean Age on Response to ACE 
Inhibitor Treatment (age*treat)
Four trials (3,4,5,11 - Appendix I) were excluded 
because of lack of data on mean age. One of the excluded 
trials was the 58,000-subject ISIS-4 trial. For the 
trials included mean age ranged from 59 to 67 years.
- 47-
Mean age had no significant impact on the pooled odds 
ratio.
The four trials excluded represent 84.7% of the subjects 
in the meta analysis. Thus, the power to detect an age 
effect is substantially reduced. Furthermore, the pooled 
odds ratio, unadjusted for covariates, of the trials 
included was 0.85 (95% confidence interval 0.77-0.93) 
which is quite different from the corresponding ratio 
overall, 0.92 (95% confidence interval 0.88-0.95). It is 
possible that the distribution of mean age is different 
for included and excluded trials; thus, there is doubt 
about the insignificant effect of mean age shown by this 
analysis.
Model 3 - Impact of Percentage of Subjects Aged 70 Years 
or Over on Response to ACE Inhibitor Treatment 
(A70* treat)
Seven trials (4,5,7,9,10,12,14 - Appendix I) were 
excluded because of lack of data on the percentage of 
subjects over the age of 70 years. In the trials 
included the percentage of subjects over the age of 70 
years varied from 15% to 42%.
The trials excluded represent 17.1% of the subjects in 
the meta analysis; thus, the power to detect an age- 
over-70 effect is unlikely to be affected substantially 
by the exclusions, and the result obtained would be 
unlikely to change substantially if the excluded trials 
were included. The unadjusted pooled odds ratio for the 
trials included was 0.93 (95% confidence interval 0.89- 
0.97) which is similar to the corresponding ratio 
overall, 0.92 (95% confidence interval 0.88-0.95).
The interaction A70*treat was significant (p<0.05). The 
variance component associated with the trial term was
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non-significant at the 5% level; thus, the A70 and 
A70*treat terms have explained some of the between-trial 
variation. The model for pooled odds ratio (OR) was as 
follows:
OR = exp(-0.07084+0.013174(A70))
with standard errors 0.02152 for the constant and 
0.005001 for the coefficient of A70.
Table 6 lists predictions of the pooled odds ratio 
obtained from this model.
TABLE 6. POOLED ODDS RATIOS OF DEATH ALL CAUSES (ACE 
INHIBITOR VERSUS PLACEBO) ADJUSTED FOR PERCENTAGE OF 
SUBJECTS 70 YEARS AND OVER
Percentage of 
Subjects 70 Years 
and Over
Pooled Odds Ratio 95% Confidence 
Interval1 of 
Pooled Odds Ratio
02 0.93 0.89-0.97
15 1.14 0.97-1.33
25 1.29 1.00-1.67
35 1.48 1.04-2.10
502 1.80 1.09-2.97
Footnotes: 1 The confidence interval is an estimate based 
on the standard errors of the constant and coefficient 
of A70.
2 Projected - the limits of the data are 15-
42%.
The predictions indicate that as the percentage of 
subjects 70 years and over increases the odds of death
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as a result of ACE inhibitor treatment increase. In 
other words, subjects 70 years and over are worse off as 
a result of ACE inhibitor treatment after myocardial 
infarction. A survival benefit is predicted only when 
there are no patients 70 years and over.
Analysis of Deaths in the Elderly Sub-Group
Six trials provided mortality data for "elderly" (age 
greater than 65 to 70 years) subjects. This data was 
used to confirm the result obtained indirectly by use of 
the trial variable A70.
The odds ratios for death (all causes) in the elderly 
subject groups of these trials are given in table 7. Age 
was greater than or equal to 70 years except where ' 
indicated.
TABLE 7. ODDS RATIOS OF DEATH ANY CAUSE (ACE INHIBITOR 
VERSUS PLACEBO) FOR "ELDERLY" SUBJECTS
No Trial No
Subjects
Odds
Ratio
95%
Confidence 
Interval of 
Odds Ratio
1 SAVE (age>=65 yrs) 783 0.77 0.58-0.96
2 CONSENSUS II 2,538 1.18 ns
3 GISSI-3 5,124 0.88 0.73-1.03
8 SMILE (age>=65 yrs) 789 0.61 0.40-0.93
11 ISIS-4 16,000 1.01 ns
12 AIRE (age>=65 yrs) ns 0.652 ns
Pooled Results 1 25,234 0.97 0.90-1.04
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Footnotes (Table 6):l Does not include AIRE study because 
of insufficient data.
2 Relative hazard, 
ns-not stated.
The pooled odds ratio and its 95% confidence interval 
indicate that the ACE inhibitor and placebo groups are 
not significantly different in respect of all-cause 
mortality in elderly subjects after myocardial 
infarction; however, there is a trend towards a survival 
benefit in the ACE inhibitor group. There may be too few 
elderly subjects in this group of trials to show a 
treatment effect.
The direct analysis of the impact of advanced age 
included six trials whereas the indirect analysis 
included seven trials. Since the results achieved by the 
two methods are contradictory (one being significant and 
the other non-significant) ,~doubt remains as to the true 
effect of advanced age and the ability of the indirect 
method to predict the impact of this covariate.
My third hypothesis, that ACE inhibitors have a greater 
impact on survival after myocardial infarction if used 
in subjects under the age of 70 years than if used in 
subjects 70 years and over, is not supported.
Model 4 - Impact of Percentage of Subjects With Heart 
Failure on Response to ACE inhibitor Treatment 
(Hfall*treat)
Four trials (4,5,6,13 - Appendix I) were excluded 
because of lack of data on the percentage of subjects 
with "heart failure", that is, for the purposes of this 
meta analysis, Killip Class > I or clinical heart 
failure. The percentage of subjects with heart failure 
varied from 14% to 100% for trials with this data.
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The trials excluded represent 14.4% of the subjects in 
the meta analysis; thus, the power to show a heart 
failure effect is not greatly affected, and the result 
is unlikely to change substantially if the excluded 
trials were included. Furthermore, the unadjusted pooled 
odds ratio for the trials included was 0.92 (95% 
confidence interval 0.87-0.96) which is similar to the 
corresponding ratio overall, 0.92 (95% confidence 
interval 0.88-0.95).
The interaction Hfail*treat was significant (p<0.05).
The variance component associated with the trial term 
was non-significant at the 5% level; thus, the Hfail and 
Hfail*treat terms have explained some of the between- 
trial variation. The model for pooled odds ratio (OR) 
was as follows:
OR = exp(-0.08472-0.003697(Hfail) )
with standard errors 0.02083 for the constant and 
0.001292 for the coefficient of Hfail.
Table 8 lists predictions of the pooled odds ratio 
obtained from this model. These predictions are plotted 
in figure 4.
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TABLE 8. POOLED ODDS RATIOS OF DEATH ALL CAUSES (ACE 
INHIBITOR VERSUS PLACEBO) ADJUSTED FOR PERCENTAGE OF 
SUBJECTS WITH HEART FAILURE
Percentage of 
Subjects with 
Heart Failure
Pooled Odds Ratio 95% Confidence 
Interval1 of 
Pooled Odds Ratio
02 0.92 0.87-0.96
25 0.84 0.77-0.91
50 0.76 0.66-0.88
75 0.70 0.57-0.85
100 0.63 0.48-0.83
Footnotes i1 The confidence interval is an estimate based 
on the standard errors of the constant and coefficient 
of Hfail.
2 Projected - the limits of the data are 14-100%.
1.00 t
0.80 -
0.60 -
0.40 -
0.20 -
12.5 25 37.5 50 62.5 75 87.5 100
% Subjects With Heart Failure
Figure 4. Impact of Percentage of Subjects With 
Heart Failure on the Deaths (All Cause) Odds Ratio
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The predictions indicate that the greater the percentage 
of subjects with some degree of heart failure after 
myocardial infarction the greater the reduction in the 
odds of death as a result of ACE inhibitor treatment.
Analysis of Deaths in the Heart Failure Sub-Group
Three trials provided mortality data for subjects with 
baseline heart failure. In the case of the SAVE trial 
(trial 1), the data refers to subjects with baseline 
ejection fractions less than or equal to 32%. This data 
is used to confirm the result obtained indirectly by use 
of the trial variable Hfail.
The odds ratios for death (all causes) for subjects with 
baseline heart failure in these trials are given in 
table 9.
TABLE 9. ODDS RATIOS OF DEATH ANY CAUSE (ACE INHIBITOR 
VERSUS PLACEBO) FOR SUBJECTS WITH BASELINE HEART FAILURE
No Trial No
Subjects
Odds
Ratio
95%
Confidence 
Interval of 
Odds Ratio
1 SAVE 1,183 0.76 0.62-0.94
2 CONSENSUS II 1,109 1.00 ns
11 ISIS-4 8,070 0.89 ns
Pooled Results 10,362 0.87 0.78-0.96
Footnotes: ns-not stated.
The pooled odds ratio and its 95% confidence interval 
indicate that ACE inhibitor treatment significantly 
reduces all-cause mortality by 13% compared with placebo
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treatment in subjects with heart failure after 
myocardial infarction.
This supports the indirect result obtained with the 
trial covariate Hfail; thus, the result is likely to be 
robust and the indirect method a good predictor in this 
case. The result supports my second hypothesis that ACE 
inhibitors have a greater impact on the survival of 
subjects with some degree of left ventricular 
dysfunction than no left ventricular dysfunction after 
myocardial infarction.
Model 5 - Impact of Percentage of Male Subjects on 
Response to ACE Inhibitor Treatment (%males*treat)
Two trials (4,5 - Appendix I) were excluded because of 
lack of data on percentage of male subjects. In the 
included trials percentage of males ranged from 56% to 
86%.
The trials excluded represent 12.8% of the subjects in 
the meta analysis; thus, the power of this analysis is 
unlikely to be substantially affected by the exclusions, 
and the result of the analysis is unlikely to change 
substantially if the excluded trials were included. The 
unadjusted pooled odds ratio for the trials included was 
0.91 (95% confidence interval 0.88-0.95) which is 
similar to the corresponding ratio overall, 0.92 (95% 
confidence interval 0.88-0.95).
The percentage of male subjects did not have a 
significant impact on the pooled odds ratio.
Analysis of Deaths in the Male and Female Sub-Groups
Six trials provided mortality data for males and/or 
females. This data was used to confirm the result
- 55-
obtained indirectly by use of the trial variable %males. 
The odds ratios for death (all causes) for males are 
given in table 10, and for females in table 11.
TABLE 10. ODDS RATIOS OF DEATH ANY CAUSE (ACE INHIBITOR 
VERSUS PLACEBO) FOR MALES
No Trial No
Subjects
Odds
Ratio
95%
Confidence 
Interval of 
Odds Ratio
1 SAVE 1,841 0.78 0.64-0.94
2 CONSENSUS II 4,447 1.03 ns
8 SMILE 1,128 0.59 0.36-0.95
11 ISIS-4 43,043 0.91 ns
12 AIRE ns 0.752 ns
Pooled Results 1 50,459 0.90 0.84-0.96
Footnotes: 1 Does not include AIRE study because of 
insufficient data 
2 Relative hazard 
ns-not stated.
The pooled odds ratio and its 95% confidence interval 
indicate that ACE inhibitor treatment significantly 
reduces all-cause mortality by 10% compared with placebo 
treatment in male subjects after myocardial infarction. 
This result compares with the non-significant result 
obtained with the trial variate %males. The direct 
method although it included only five trials compared 
with 12 for the indirect method still contained a 
substantial proportion of the subjects (the number of 
male subjects in the five trials is almost half of all 
subjects included in this review). Thus, the indirect
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method appears to have been a poor predictor of the 
effect of male sex in this instance.
TABLE 11. ODDS RATIOS OF DEATH ANY CAUSE (ACE INHIBITOR 
VERSUS PLACEBO) FOR FEMALES
No Trial No
Subjects
Odds
Ratio
95%
Confidence 
Interval of 
Odds Ratio
1 SAVE 390 0.98 0.63-1.53
2 CONSENSUS II 1, 643 1.21 ns
3 GISSI-3 4,191 0.81 0.62-1.00
8 SMILE 428 0.70 0.40-1.21
11 ISIS-4 15,000 0.97 ns
12 AIRE ns 0.702 ns
Pooled Results 1 21,652 0.95 0.87-1.03
Footnotes: 1 Does not include AIRE study because of 
insufficient data 
2 Relative hazard 
ns-not stated.
The pooled odds ratio and its 95% confidence interval in 
Table 11 indicate that the ACE inhibitor and placebo 
groups are not significantly different in respect of 
all-cause mortality in females after myocardial 
infarction; however, there is a trend towards a survival 
benefit in the ACE inhibitor group. There may be too few 
female subjects in these trials to show a treatment 
effect.
My fourth hypothesis, that ACE inhibitors after
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myocardial infarction have an equal impact on survival 
for males and females is not disproved. The direct 
method produced a significant survival benefit for males 
and a trend towards benefit in females.
Model 6 - Impact of Mean Duration of Treatment on 
Response to ACE Inhibitor Treatment (durT* treat)
One trial (4- Appendix I) was excluded because'of lack 
of data on mean duration of treatment. In the other 
trials mean duration of treatment ranged from one month 
to 42 months.
The unadjusted pooled odds ratio for the trials included 
was the same as the corresponding ratio overall, 0.92 
(95% confidence interval 0.88-0.95), because of the 
negligible impact of excluding trial 4 (Lu et al), which 
contained only 98 subjects (0.1% of the subjects in the 
meta analysis). The power of the analysis to detect a 
duration-of-treatment effect is unlikely to be affected 
substantially by the exclusion of trial 4.
The terms In(durT) and In(durT)*treat were significant 
(p<0.005). These effects are likely to be robust because 
of the negligible impact on power caused by the 
exclusion of trial 4. The variance component associated 
with the trial term was non-significant at the 5% level 
suggesting that durT and durT*treat have explained some 
of the between-trial heterogeneity. The model obtained 
for the pooled odds ratio (OR) was as follows:
OR = exp(-0.08581-0.05878*ln(durT))
with standard errors 0.01944 for the constant and 
0.01776 for the coefficient of In(durT).
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Table 12 lists predictions of the pooled odds ratio 
obtained from this model. The predictions are plotted in 
figure 5.
TABLE 12. POOLED ODDS RATIOS OF DEATH ALL CAUSES (ACE 
INHIBITOR VERSUS PLACEBO) ADJUSTED FOR MEAN DURATION OF 
TREATMENT
Mean Duration of 
Treatment (months)
Pooled Odds Ratio 95% Confidence 
Interval1 of 
Pooled Odds Ratio
0.52 0.96 0.91-1.00
1 0.92 0.88-0.95
2 0.88 0.84-0.92
3 0.86 0.81-0.91
6 0.83 0.77-0.89
12 0.79 0.72-0.87
24 0.76 0.68-0.86
ivjCD 0.73 0.63-0.84
Footnotes: 1 The confidence interval is an estimate based 
on the standard errors of the constant and coefficient 
of In(durT).
2 Projected - the limits of the data are 1-48
mths.
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Figure 5. Impact of Mean Duration of
Treatment on the Deaths (All Cause)
Odds Ratio
The predictions indicate that the longer the treatment 
duration the greater the reduction in the odds of death 
as a result of ACE inhibitor treatment after myocardial 
infarction. The reduction in odds is particularly 
substantial for mean treatment durations of 12 months or 
greater. However, the marginal benefits diminish the 
greater the duration of treatment. Doubling the 
treatment duration produces an additional odds reduction 
for death of 3%.
My fifth hypothesis, that a treatment duration of at 
least one month is needed for ACE inhibitors to improve 
survival after myocardial infarction, could not be 
tested directly because no trial had a duration of
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treatment less than one month. The model predicts a 
significant benefit at a duration of treatment of 0.5 
months; however, such a prediction may be wrong since it 
is beyond the limit of the data in the trials.
Model 7 - Impact of Mean Duration of Follow-Up on 
Response to ACE Inhibitor Treatment (durF*treat)
One trial (4- Appendix I) was excluded because of lack 
of data on mean duration of follow-up. In the other 
trials mean duration of treatment ranged from one month 
to 42 months.
As in model 6, the exclusion of trial 4 has a negligible 
impact on the power to detect a duration-of-follow-up 
effect.
The term In(durF) was significant (p<0.005) but not the 
interaction term In(durF)*treat. These are likely to be 
true effects in view of the power of this analysis.
Trial was non-significant at the 5% level; thus, durF 
explains some of the between-trial heterogeneity.
Because there was no interaction between durF and treat, 
the pooled odds ratio was independent of the mean 
duration of follow-up.
7.2 Deaths - Cardiovascular Causes
7.21 Analysis of Individual Trials
Four of the 14 trials quoted the number of deaths from 
cardiovascular causes. The odds ratios and 95% 
confidence intervals for each trial for this measure are 
given in Table 13, and plotted in figure 6.
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TABLE 13. ODDS RATIOS OF CARDIOVASCULAR DEATH (ACE 
INHIBITOR VERSUS PLACEBO) OBTAINED USING REVMAN
No Trial No Deaths/ 
No Subjects
Odds
Ratio
95%
Confidence 
Interval 
of Odds 
Ratio
ACE
Inhib
Placebo
1 SAVE 188/ 234/ 0.77 0.62-0.95
1115 1116
2 CONSENSUS II 299/ 270/ 1.12 0.94-1.33
3044 3046
6 PRACTICAL 8/ 0.63 0.25-1.62
Captopril 75 12/
6 PRACTICAL 1/ 75 0.16 0.05-0.49
Enalapril 75
7 SMILE Pilot 8/ 11/ 0.72 0.28-1.85
101 103
POOLED 504/ 527/ 0.94 0.82-1.07
4410 4340
Between-trial test for heterogeneity; x2 (df=4) 17.97.
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Figure 6. Cardiovascular Death Odds 
Ratios and 95% Confidence Intervals 
for Included Trials
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ACE inhibitor treatment significantly (p<0.05) reduced 
cardiovascular deaths compared with placebo in 2 trials, 
and there was a non-significant result in 3 trials (the 
PRACTICAL trial being counted twice because of its three 
treatment arms).
7.22 Combined Analysis
For cardiovascular deaths the model produced a pooled 
odds ratio of 0.94 with 95% confidence interval 0.82- 
1.07. This result is similar to the result obtained by 
the Peto Method (0.93 with 95% confidence interval 0.81- 
1.06). The odds ratio estimate from the DerSimonian and 
Laird Method was lower (0.80 with 95% confidence 
interval 0.55-1.16).
There were too few trials with data on cardiovascular 
deaths to examine the impact of covariates.
7.3 Model Diagnostics
The model diagnostic checks were satisfactory for all 
models fitted. The diagnostic plots are attached as 
Appendix III.
7.4 Impact of ISIS-4
The very large ISIS-4 trial which provides about half 
the subjects in this meta analysis was removed to assess 
its impact.
Model with Treatment Only
Removal of the ISIS-4 trial reduced the pooled odds 
ratio from 0.92 (95% confidence interval 0.88-0.95) to 
0.87 (95% confidence interval 0.82-0.93). Thus, the
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ISIS-4 trial does have an impact; however, it is not a 
significant impact since the 95% confidence interval for 
odds ratio overall and the ratio without ISIS-4 overlap. 
Removal of this trial did not alter the between-trial 
heterogeneity.
Models with Treatment and Other Covarlates
Com (time of commencing treatment) remained a 
significant term and the pooled odds ratios were 
virtually unchanged when the ISIS-4 trial was removed; 
thus, the significance of com is quite robust. The ISIS- 
4 trial commenced treatment within 48 hours of 
infarction as did ten other trials. The combined 
information from the ten other trials was sufficient to 
predict the impact of treatment within 48 hours of 
infarction, and to conclude that commencement of ACE 
inhibitor treatment too early after infarction lessens 
the survival benefit.
Hfail (proportion of subjects with heart failure) and 
durT (mean duration of treatment) remained significant 
terms when ISIS-4 was removed; however, the estimates of 
odds ratio favoured the ACE inhibitor group for lower 
proportions of heart failure subjects enrolled, and for 
shorter mean durations of treatment, a situation which 
is unlikely. The ISIS-4 trial appears to have been of 
borderline significance because it was unselective in 
terms of the degree of heart failure (only 14% of 
subjects enrolled had heart failure), and the duration 
of treatment (one month) was too short. The meta 
analysis with ISIS-4 included is reflecting this.
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8. Discussion
8 . 1 A  Priori Hypotheses
It is clear from this meta analysis of 14 trials that 
ACE inhibitors do significantly reduce deaths after 
myocardial infarction. Overall, the risk reduction was 
8% (95% confidence interval 5 to 12%) compared with 
placebo. However, the trials were heterogeneous in their 
results; thus, it is inappropriate to quote merely the 
overall figure for risk reduction.
It was found that, at trial level, the time of 
commencing treatment after infarction, the proportion of 
subjects with some degree of heart failure, and the mean 
duration of treatment significantly alter the risk 
reduction and explain some of the heterogeneity amongst 
trials. These trial level results provide an indication 
that time of commencing treatment, degree of heart 
failure and duration of treatment may be important at 
the individual level.
Five hypotheses were made a priori. These hypotheses are 
re-stated in Table 14 with the corresponding outcomes 
from this meta analysis. The table provides the outcomes 
for all-cause mortality only. There was insufficient 
data to draw conclusions on the other effect measure, 
cardiovascular mortality.
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TABLE 14. EVIDENCE FROM THE META ANALYSIS SUPPORTING THE 
A PRIORI HYPOTHESES
No Hypothesis Result
1 ACE inhibitors diminish Supported - optimal
survival benefit if commencement time 1-6 days
started earlier than 24 after myocardial
hours after a myocardial 
infarction
infarction.
2 ACE inhibitors have a Supported - trial
greater impact on the covariate, proportion of
survival of subjects with subjects with heart
some degree of left failure, significant
ventricular dysfunction (p<0.05, figure 4); subject
than no left ventricular covariate, presence of
dysfunction after heart failure, significant
myocardial infarction on sub-group analysis: odds 
ratio 0.87 (95% Cl: 0.78- 
0.96) .
3 ACE inhibitors have a Not Supported - trial
greater impact on survival covariate, proportion of
after myocardial subjects over age 70 years,
infarction if used in significant (p<0.05);
subjects under the age of subject covariate, age over
70 years than if used in 70 years, not significant
subjects 70 years and over on sub-group analysis.
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TABLE 14 (CONT). EVIDENCE FROM THE META ANALYSIS 
SUPPORTING THE A PRIORI HYPOTHESES
No Hypothesis Result
4 ACE inhibitors after Not Disproved - trial
myocardial infarction have covariate, %males, not
an equal impact on significant; subject
survival for males and covariate, male,
females significant (p<0.05) on 
sub-group analysis: odds 
ratio 0.90 (95% CI:0.84- 
0.96); insufficient data on 
females.
5 A treatment duration of at Not Disproved - no data on
least one month is-needed treatment duration < 1
for ACE inhibitors to month. Data suggest at
improve survival after least 12 months treatment
myocardial infarction before diminishing returns 
(figure 5).
The results suggest that the optimum treatment 
population includes subjects with some degree of heart 
failure; the optimum treatment regime includes 
commencement of ACE inhibitor beyond 24 hours after 
infarction; and the optimum duration of treatment is at 
least 12 months.
8.2 Validity of the Results
Biological and methodological factors provide validity 
for the results. The results are also supported by 
current opinion.
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Biologlcal Plausibility
Biological processes after myocardial infarction, and 
mechanisms of ACE inhibitor action were discussed in the 
Introduction. Soon after infarction, the myocardium is 
sensitive to the hypotensive insult induced by ACE 
inhibitors. Thus, ACE inhibitor treatment cannot begin 
too soon. On the other hand, to achieve maximal 
inhibition of the renin-angiotensin system, which is a 
factor in stabilising the infarct, treatment must begin 
within 72 hours. This supports the hypothesis that ACE 
inhibitors should not be started sooner than 24 hours 
after myocardial infarction.
The sympathetic and renin-angiotensin system activation 
after infarction is greater in patients with left 
ventricular dysfunction compared with other patients. 
Curbing the activity of these systems in patients with 
some degree of left ventricular dysfunction would then 
be expected to have a greater impact. This supports the 
greater reduction in mortality in patients with heart 
failure treated with ACE inhibitors.
It is believed that ACE inhibitors have anti-ischaemic 
and anti-plaque effects. If this is the case then 
additional survival benefits could be expected from 
longer treatment, which supports the hypothesis of 
greater survival for longer durations of ACE inhibitor 
treatment.
Methodological Plausibility
The model diagnostic checks were satisfactory. All 
trials except three fitted the models reasonably well. 
The three exceptions were ISIS-4 Phase 2/3, PRACTICAL- 
Enalapril and CONSENSUS II, which were outliers in the 
three significant models (those involving time of
- 69-
commencement of ACE inhibitor, proportion of subjects 
with heart failure and mean duration of treatment). The 
ISIS-4 Phase 2/3 and PRACTICAL-Enalapril trials were 
very small (474 and 150 subjects respectively) which may 
explain their outlier status. The outlier status of the 
CONSENSUS II trial, which enrolled 6,090 subjects, is 
more difficult to explain. The premature termination of 
this trial after six months may have been a factor: a 
benefit may have been achieved if the trial had been 
continued for 12 months. Support for this is provided by 
the SAVE trial which took ten months to show a 
significant survival benefit for ACE inhibitors.
Sensitivity analysis indicated that the quality of the 
included trials was not an important issue, the result 
being the same if trials of doubtful quality were 
removed. This was expected since only randomised 
controlled trials were included in this review.
From discussions with colleagues it is unlikely that any 
important trials have been missed. The meta analysis 
covered more than 107,000 subjects and 12,000 events 
(deaths); thus, a chance result is unlikely.
The unadjusted results for the mixed model were similar 
to results obtained using the traditional methods of 
Peto, and DerSimonian and Laird.
Current Opinion
A key current issue is whether to give all patients an 
ACE inhibitor after myocardial infarction or to be 
selective and give ACE inhibitors only to those patients 
with some degree of left ventricular dysfunction after 
myocardial infarction (provided the left ventricular 
function is not so poor as to cause severe hypotension 
if an ACE inhibitor were to be given). Current opinion
- 70-
is to be selective (46,57-65). This is the stance taken 
by regulatory authorities such as the US Food and Drug 
Administration and the Australian Therapeutic Goods 
Administration. There was a greater reduction in the 
risk of death achieved with ACE inhibitor treatment in 
the selective trials (SAVE,AIRE, TRACE) compared with the 
non-selective trials. The three selective trials were 
significant (p<0.05) whereas only four of the eleven 
non-selective trials were significant. The meta analysis 
demonstrated the significant impact of percentage of 
subjects with some degree of heart failure on the odds 
of death, which is consistent with this opinion.
Patients developing severe hypotension after a test dose 
of ACE inhibitor were excluded from the trials examined 
in the meta analysis. ACE inhibitors are contraindicated 
in this group of patients.
Another current issue is the time of commencement of ACE 
inhibitor treatment after infarction. Opinion is to 
delay the commencement of treatment for 24 hours, or 
until patients are haemodynamically stable 
(57,58,62,65,66,67). This opinion is based largely on 
the negative result of the CONSENSUS II trial. The meta 
analysis supports this opinion, a 6% reduction in the 
odds of death being achieved from ACE inhibitor 
treatment begun within 48 hours of infarction, and a 25% 
reduction for ACE inhibitor treatment begun later.
A further issue is duration of treatment. Opinion is 
that long-term treatment is unjustified unless there is 
congestive cardiac failure (68,58). The meta analysis 
suggests that the benefits are enhanced the longer the 
duration of treatment; however, it also suggests that 
there is a point of diminishing returns which occurs at 
about 12 months treatment. In the individual trials 
there were marked differences in time to show a survival 
benefit, for example, in the SAVE trial 10 months of
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continuous captopril treatment was necessary before a 
significant difference between the captopril and placebo 
group emerged, and the CONSENSUS II trial had not shown 
a benefit after six months of enalapril treatment. On 
the other hand, the AIRE (ramipril) and ISIS-4 
(captopril) trials were showing significant survival 
benefit for ACE inhibitor after only four weeks 
treatment.
8.3 Limitations
The randomisation was only to ACE inhibitor treatment or 
no ACE inhibitor treatment. There may be confounding 
(interaction) amongst the other covariates. Confounding 
could be detected by multivariate logistic regression; 
however, there were insufficient degrees of freedom and 
data to permit this.
The covariate effects were tested at trial level and 
inference made about outcomes in individuals. Whilst, 
the trial covariates examined could, in some cases, 
explain heterogeneity amongst trials, their ability to 
predict effects in individuals was not robust, except in 
the case of the covariate Hfail.
The trials were spread over a 10-year period during 
which thrombolysis was introduced. Thus, there may be an 
era effect. This could be tested as a trial covariate in 
the mixed model.
Whilst use of total mortality as the outcome measure 
provides a good global indication of whether there is a 
benefit from treatment or not, the use of outcomes other 
than death may give some insight into why ACE inhibitors 
reduce mortality after myocardial infarction and provide 
information on other effects of treatment (3). For 
example, endpoints related to coronary artery disease
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(preventing re-infarction) and development of congestive 
cardiac failure may be interesting since individual 
trials such as SAVE and AIRE provide evidence that ACE 
inhibitors may alter the natural history of coronary 
artery disease (reduced re-infarctions) and left 
ventricular dysfunction (reduced development of 
congestive cardiac failure) (57) .
The studies included have different average durations of 
follow-up; thus, the fields of risk are different. To 
account for the different fields of risk as a result of 
the different durations of follow-up, the mean duration 
of follow-up was included as a trial covariate in the 
regression model. Surprisingly, there was no interaction 
between mean duration of follow-up and treatment; 
however, there was an interaction between mean duration 
of treatment and treatment. These factors need to be 
examined in more detail at sub-group level, that is, 
analysis of outcomes for several ranges of treatment 
duration and follow-up duration.
Since death is not an uncommon outcome after myocardial 
infarction, Cox proportional hazards models of times to 
death may be more appropriate than logistic regression. 
Whilst the logistic regression coefficient for the 
treatment effect approximates the corresponding Cox 
model coefficient for rare conditions this is not the 
case for common conditions (11). A Cox regression 
analysis would require individual patient data on 
survival times.
The impact of the type of ACE inhibitor may be 
important. For example, in this meta analysis there were 
six ACE inhibitors, two short-acting (captopril, 
zofenopril), and four long-acting (enalapril, 
lisinopril, ramipril, trandolapril). Of the nine studies 
involving short-acting ACE inhibitors only three were
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significant, whereas, of the six studies involving long- 
acting ACE inhibitors, four were significant. Thus, the 
more sustained action of the long-acting ACE inhibitors 
may be a factor in enhancing survival.
The site of the myocardial infarction may also be an 
important factor. Subjects with anterior infarctions, 
for example, are believed to have a poorer prognosis.
9. Implications for Policy and Future Research 
9.1 Policy
The approach to meta analysis used in this review, that 
is examining the impact of covariates at trial level, is 
exploratory. It provides the broad picture of whether a 
treatment is effective or not, and what the likely 
factors influencing outcome are. It, therefore, provides 
the direction for policy and future research. This is 
true of meta analysis generally (69).
The results can be converted from odds ratios to 
absolute benefit measures, which are more meaningful in 
the clinical context. The number of patients who need to 
be treated to prevent one death, which can be obtained 
from the reciprocal of the absolute risk reduction, is a 
meaningful absolute measure (70).
From Table 3 the pooled absolute risk reduction for 
death as a result of ACE inhibitor treatment is 0.0083 
which means that one death is prevented per 120 patients 
treated. If only the trials where ACE inhibitor 
treatment commenced beyond 48 hours are considered, the 
pooled absolute risk reduction is 0.0549, which is a 
substantial improvement since one death is prevented per 
18 patients treated.
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In the Australian context, answers to broad questions 
provided by meta analyses may influence decisions with 
respect to the listing of procedures in the Medicare 
Benefits Schedule, and the listing of drugs on the 
Pharmaceutical Benefits Schedule. A finding of benefit 
on a meta analysis is a reasonable basis on which to 
decide the allocation of scarce health resources.
Broad results from meta analysis may also influence drug 
regulatory decisions by the Therapeutic Goods 
Administration and the development of Clinical Practice 
Guidelines by the National Health and Medical Research 
Council; however, these activities usually require more 
detailed information, for example, with respect to 
patient population, dosage and duration of treatment.
The US Food and Drugs Administration has taken 
regulatory action on the basis of a meta analysis. It 
approved the use of aspirin to reduce the risk of death 
and/or non-fatal myocardial infarction in patients with 
a previous infarction (71).
Meta analysis can provide answers to more specific 
questions when individual patient data is available, 
thus, allowing sub-group analysis. More resources are 
required for sub-group analysis. In the case of the use 
of ACE inhibitors in myocardial infarction, where there 
was insufficient published information, sub-group 
analysis would require the co-operation of several 
trialists in providing the data and the analysis of over 
100,000 records.
A more detailed analysis at sub-group level, which could 
also be done using the mixed model approach, is needed 
to test the impact of important prognostic and 
epidemiological factors. Such information is usually 
required for drug regulatory decisions and the
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development of clinical guidelines. Some factors for 
analysis are suggested under 9.2 Future Research.
The maximum likelihood estimates for pooled odds ratios 
obtained from the mixed logistic regression model were 
very similar to the Peto and DerSimonian and Laird 
pooled odds ratio estimates. Regression models, unlike 
Peto and DerSimonian and Laird, have the advantage of 
examining the impact of covariates on pooled odds 
ratios. Logistic regression may be an appropriate method 
for the Cochrane Collaboration to use in the future.
The development of computer software for meta analysis 
and greater facility to analyse sub-groups from large 
trials in a meta analysis will increase the use of meta 
analysis in clinical decision-making as well as in 
policy areas. For the present, clinicians will continue 
to rely chiefly on the results of individual clinical 
trials for the most reliable'estimates of treatment 
effect and the optimum patient population and treatment 
regimen (2).
9.2 Future Research
Several avenues of investigation remain with respect to 
the use of ACE inhibitors after myocardial infarction. 
Investigations are needed at both the trial level and 
the sub-group level. The mixed model approach employed 
in this review is appropriate at both levels. Some 
factors for consideration are:
- Other Covariates
Site of myocardial infarction e.g. anterior 
Type of ACE inhibitor, whether short-acting or 
long-acting 
Era effect
Dosage of ACE inhibitor
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- Other Endpoints
Incidence of heart failure 
Recurrent myocardial infarction 
Stroke
Hospitalisation for heart failure 
Times to specific events such as death
- Sub-Group Analysis
Outcomes in various age groups 
Outcomes in males and females 
Outcomes for various ranges of commencement 
times after infarction to pin-point the 
sensitive period
Outcomes for various degrees of cardiac 
failure
Outcomes for various ranges of treatment 
duration and follow-up duration.
It is proposed to examine some of these factors in the 
McMaster study in which the-cooperation of several 
trialists has been obtained for the provision of 
individual patient data from the major trials (72).
9.3 Conclusion
In this review the mixed model method has been applied 
to analysis of outcomes at the trial level. It could 
also be applied to analysis of outcomes at the sub-group 
level. The value of the analysis employed here at trial 
level is to identify sources of heterogeneity in 
outcomes amongst trials as a prelude to analysis of 
outcomes in sub-groups. The method provides an 
expeditious means of identifying trends and providing 
policy and research directions without the need to 
resort to individual patient data from trialists. 
However, sub-group analysis using individual patient 
data is also needed for the proper development of 
clinical practice guidelines.
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Appendix I - Data Extracted for Meta Analysis
Tr
ia
1
Tr
t
Co
m
%Mal
es
Age A 70 H
fail
Dur
T
Dur
F
Tdea
th
Cdea
th
N o .
Subj
1 1 1 83 5 9 . 3 15 40 42 42 228 188 1115
1 0 1 82 5 9 . 5 15 41 42 42 275 234 1116
2 1 0 73 6 5 . 7 4 2 . 3 18 6 6 312 299 3044
2 0 0 74 6 5 . 8 4 1 . 0 19 6 6 286 270 3046
3 1 0 7 7 . 7 - 1 2 6 . 8 1 4 . 1 1 . 5 1 . 5 597 - 1 9435
3 0 0 7 7 . 9 -1 2 7 . 4 1 4 . 9 1 . 5 1 . 5 673 - 1 9460
4 1 0 - 1 -1 -1 -1 -1 - 1 3 - 1 43
4 0 0 - 1 -1 - 1 - 1 -1 - 1 8 - 1 55
5 1 0 - 1 - 1 - 1 - 1 1 1 617 - 1 6814
5 0 0 - 1 - 1 -1 -1 1 1 654 - 1 6820
6 1 0 56 64 23 -1 12 12 10 8 75
6 1 0 59 63 28 _ i_ 12 12 2 1 75
6 0 0 58 64 27 - 1 12 12 12 12 75
7 1 0 8 6 . 3 60. '7 - 1 1 8 . 8 12 12 8 8 101
7 0 0 8 1 . 6 6 1 . 1 - 1 1 8 . 2 12 12 11 11 103
8 1 0 72 6 3 . 9 29 15 6 12 77 - 1 772
8 0 0 73 6 4 . 3 31 14 6 12 111 - 1 784
9 1 0 78 61 - 1 35 1 1 3 - 1 133
9 0 0 82 62 - 1 35 1 1 5 - 1 134
10 1 0 77 59 - 1 19 1 1 21 - 1 237
10 0 0 76 60 - 1 19 1 1 14 - 1 237
11 1 0 74 -1 28 1 4 . 5 1 12 3480 - 1 29028
11 0 0 74 - 1 28 1 6 . 0 1 12 3636 - 1 29022
12 1 1 73 6 4 . 9 - 1 100 15 15 170 - 1 1014
12 0 1 74 6 5 .1 - 1 100 15 15 222 - 1 992
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Data Extracted (cont)
Tr
ia
1
Tr
t
Co
m
%Mal
es
Age A7 0 H
fail
Dur
T
Dur
F
Tdea
th
Cdea
th
No.
Subj
13 1 0 76 64 31 -1 1.5 1.5 41 -1 509
13 0 0 76 64 31 -1 1.5 1.5 98 -1 1017
14 1 1 67.2 67.3 -1 18.7 36 36 307 -1 876
14 0 1 67.2 67.3 -1 18.7 36 36 366 -1 873
Legend:
Trial Numbers: 1-SAVE, 2-CONSENSUS II, 3-GISSI3, 4-Lu, 5- 
CCS, 6-PRACTICAL, 7-SMILE Pilot, 8-SMILE, 9-ISIS4 Pilot 
Phase 1, 10-ISIS4 Pilot Phase 2/3, 11-ISIS4,
12-AIRE, 13-GISSI3 Pilot, 14-TRACE.
Trt
Com
%Males 
Age 
A7 0 
Hf ail
DurT
DurF
Tdeath
Cdeath
-1
Treatment: 0-Placebo, 1-ACE Inhibitor 
Time of Commencing Treatment After Infarct: 
O-Within 48 Hours, 1-After 48 Hours 
Percentage of Subjects Who Were Male 
Mean Age of Subjects (Years)
Percentage of Subjects Aged Over 70 Years 
Percentage of Subjects of Killip Class > I, or 
with Heart Failure Clinically 
Mean Duration of Treatment (Months)
Mean Duration of Follow-Up (Months)
Total Deaths (Any Cause)
Deaths due to Cardiovascular Causes 
Missing Data.
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Notes ;
1. When the group break-up was not available for %Males, 
Age, A70 or Hfail (trials 9,11,13,14), it was assumed 
that both groups were equal, which is the likely 
situation for randomised trials.
2. Intention-to-treat data was not available for 
trial 3.
3. The Lu et al study commenced ACE inhibitors "early" 
after myocardial infarction. I interpreted "early" as 
being within 48 hours.
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Appendix II - Descriptions of Trials Included
Survival and Ventricular Enlargement (SAVE) Study/ 1987- 
90, USA and Canada (33)
Design: Randomised, double-blind, placebo-controlled, 
parallel. Computer-generated assignment, stratified by 
centre.
Diagnosis: 3-16 days after myocardial infarction (av 11 
days in both groups).
Number of Subjects:
- captopril group 1,115
- placebo group 1,116
Subject Characteristics:
* Males
- captopril group 83%
- placebo group 82%
* Mean Age (Years)
- captopril group 59.3
- placebo group 59.5
* Age > 70 years
- captopril group 15%
- placebo group 15%
* Degree of left ventricular dysfunction
- ejection fraction <= 40% (av 31% in both 
groups)
- Killip class > I: 40% of captopril group and 
41% of placebo group
- no overt heart failure
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* no overt myocardial ischaemia or hypotension and could 
tolerate a test dose of captopril 6.25 mg orally
* Thrombolytic Therapy: captopril 34%, placebo 32%
* PTCA: captopril 7%, placebo 17%
* CABG: captopril 10%, placebo 8%
ACE Inhibitor Treatment: captopril
* Initially 6.25-12.5 mg daily
* Increased gradually to a maximum of 50 mg three times 
daily
Duration: 42 months (average), 24-60 months (range) 
Endpoints: total mortality,-cardiovascular mortality
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Results (Intention-to-treat analysis): 
Total Mortality (av follow-up 42 months)
Captopril Placebo Risk Reduction% 
(95% Cl)
All
Subj ects
228/1115
(20.4%)
275/1116
(24.6%)
19 (3-32) 
p=0.019
Age <= 64 
years
121/731
(16.6%)
131/717
(18.3%)
8 (-34-37) 
age<=55 years 
13 (-21-37) 
age 56-64 years
Age > 64 
years
107/384
(27.9%)
144/399
(36.1%)
25 (4-42)
Male 191/929
(20.6%)
234/912
(25.7%)
22 (6-36)
Female 37/186
(19.9%)
41/204
(20.1%)
2 (-53-37)
EF <= 32% 153/584
(26.2%)
198/599
(33.1%)
24 (6-38)
EF > 32% 75/531
(14.1%)
77/517
(14.9%)
6 (-29-32)
Thrombo-
lytics
48/376
(12.8%)
58/355
(16.3%)
22 (-14-47)
No Throm- 
bolytics
180/739
(24.4%)
217/761
(28.5%)
17 (-1-32)
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Cardiovascular Mortality (av follow-up 42 months)
Captopril Placebo Risk Reduction! 
(95% Cl)
All
Subj ects
188/1115
(16.9%)
234/1116
(21.0%)
21 (5-35) 
p=0.014
Note - Risk Reduction based on life-table analysis.
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Cooperative New Scandinavian Enalapril Survival Study II 
(CONSENSUS II), 1990-91, Denmark, Finland, Iceland, 
Norway, Sweden (36)
Design: Randomised, double-blind, placebo-controlled, 
parallel.
Diagnosis: within 24 hours of the onset of chest pain 
(av. 15 hours in both groups).
Number of Subjects:
- enalapril group 3,044
- placebo group 3,046
Subject Characteristics:
* Males
- enalapril group 73%
- placebo group ~ 74%
* Mean Age (Years)
- enalapril group 65.7
- placebo group 65.8
* Age > 70 years
not stated
* Degree of left ventricular dysfunction
- none to severe
- heart failure: enalapril 18%, placebo 19%
* Blood Pressure > 100/60 mmHg (later changed to 105/65)
* Hypotension (systolic blood pressure < 90 mmHg): 11% 
in both groups at baseline
* Thrombolytic Therapy: 56% in each group
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ACE Inhibitor Treatment:
* Initially 1 mg enalaprilat in 100 mL normal saline by 
intravenous infusion over 2 hours
* Six hours after the infusion, enalapril orally 
starting at 2.5 mg twice daily and increasing gradually 
to a maximum of 20 mg daily as tolerated
Duration: 41 to 180 days; 48.5% received 180 days 
treatment before the trial was prematurely stopped.
Endpoints: total mortality, cardiovascular mortality
Results (Intention-To-Treat) - Total Mortality (48.5% 
achieved max 6 months follow-up)
Enalapril Placebo Risk Reduction% 
(95% Cl)
All
Subj ects
312/3044
(10.2%)
286/3046
(9.4%)
-10 (-29-7)
p=0.2 6
Age < 70 
years
88/1756
(5.0%)
101/1796
(5.6%)
11
Age >= 70 
years
223/1288
(17.3%)
184/1250
(14.7%)
-18
Male 199/2208
(9.0%)
196/2239
(8.8%)
-3
Female 113/836
(13.5%)
90/807
(11.2%)
-21
Heart
Failure
97/541
(18%)
108/568
(19%)
0 (s ame 
mortality in 
each group)
Thrombo-
lytics
135/1702
(7.8%)
121/1712
(7.0%)
-12
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Note - Risk Reduction (all subjects) is based on the 
survival curve; risk reductions for sub-groups are based 
on mortality rates at the end of the study.
* Life-Table Mortality (%)
Enalapril Placebo Relative Risk (95% Cl)
10 days 4.6% 4.3%
1 month 7.2% 6.3%
3 months 9.1% 8.2%
6 months 11.0% 10.2% 1.10 (0.93-1.29)
* Cardiovascular Mortality
Enalapril Placebo Odds Ratio (95% Cl)
All
Subj ects
299/3044
(9.8%)
270/3046
(8.9%)
1.12 (0.57-1.20)
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Gruppo Itallano per lo Studio della Soprawlvenza 
nell'Infarto Mlocardlco (GISSI-3) Pilot Study, 1991-3, 
Italy (43)
Design: Randomised, open-label, placebo-controlled. 
Subjects were randomly assigned to one of three 
treatment groups: lisinopril, nitroglycerin or placebo.
Diagnosis: within 24 hours of suspected acute myocardial 
infarction.
Number of Subjects:
- lisinopril group 509
- nitrate and
placebo group 1,017
Subject Characteristics:
* Males
- 761 (group break-up not given)
* Mean Age (Years)
- 64 years,sd 11 years (group break-up not given)
* Age > 70 years
- 31% (group break-up not given)
* Degree of left ventricular dysfunction
- not stated
* Systolic Blood Pressure > 100 mmHg
* Thrombolytic Therapy
- 67% (group break-up not given)
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ACE Inhibitor Treatment: lisinopril
* An oral dose of 5 mg per day for the first 2 days
* Subsequently 10 mg orally daily maximum.
Duration: 6 weeks.
Endpoint: total mortality (after 6 weeks follow-up). 
Results - Total Mortality (6 weeks)
Lisinopril Placebo Odds Ratio 
(95% Cl)
All
Subj ects
41/509
(8.1%)
98/1017
(9.6%)
0.83
(0.57-1.20)
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Gruppo Itallano per lo Studio della Soprawlvenza 
nell'Infarto Mlocardlco (GISSI-3), 1991-3, Italy (34)
Design: Randomised, open-label, placebo-controlled. In a 
2x2 factorial design subjects were randomly assigned to 
one of four treatment groups: lisinopril alone, nitrates 
alone, combined therapy, and placebo.
Diagnosis: within 24 hours of suspected acute myocardial 
infarction (35% less than 6 hours from symptom onset).
Number of Subjects:
- lisinopril group 9,435
- placebo group 9,460
- others randomised 399 (no follow-up)
Subject Characteristics:
* Males
- lisinopril group 77.7%
- placebo group 77.9%
* Mean Age (Years)
not stated
* Age >70 years
- lisinopril group 26.8%
- placebo group 27.4%
* Degree of left ventricular dysfunction
- none to severe
- Killip class > 1: lisinopril 14.1%, placebo 14.9% 
(except excluded Killip class 4 subjects)
* Systolic Blood Pressure > 100 mmHg
★ Thrombolytic Therapy: lisinopril 71.4%, placebo 71.9%
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ACE Inhibitor Treatment: lisinopril
* Initially an oral dose of 2.5-5 mg
* Subsequently 10 mg orally daily maximum (47.5% of 
subjects received the maximum dose)
* non-protocol treatment with ACE inhibitors was allowed 
(13.3% of placebo subjects took non-study ACE 
inhibitors)
Duration: 6 weeks.
Endpoint: total mortality.
Results: Analysis on subjects with follow-up data (97.4% 
of those randomised)
* Total Mortality (6 weeks)
Lisinopril Placebo Odds Ratio 
(95% Cl)
All
Subj ects
597/9435
(6.3%)
673/9460
(7.1%)
0.88
(0.79-0.99) 
p=0.03
Age >70 
years
354/2532
(14.0%)
404/2592
(15.6%)
0.88
(0.73-1.03)
Female 225/2103
(10.7%)
269/2088
(12.9%)
0.81
(0.62-1.00)
Note - Odds Ratio is based on the survival curve.
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LU,CY et al. Treatment of Acute Myocardial Infarction 
with Oral Captopril: A Randomised Double-Blind Placebo- 
Controlled Pilot Study (44)
Information obtained from the English Medline abstract: 
Design: Randomised, double-blind, placebo-controlled. 
Diagnosis: "Early stage" of acute myocardial infarction.
Number of Subjects:
- captopril group 43
- placebo group 55
Subject Characteristics:
not stated in abstract
ACE Inhibitor Treatment: captopril
* Initially 6.25 mg orally daily
* Maximum not stated in abstract but 12.5 mg dose also 
used.
Duration: Not stated in abstract.
Endpoint: total mortality 
Results: Intention-to-treat analysis
Captopril Placebo Odds Ratio 
(95% Cl)
3/43
(7.0%)
8/55
(14.5%)
0.47
(0.13-1.66)
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Placebo-Controiled Randomised ACE Inhibitor Comparative 
Trial In Cardiac Infarction and LV Function (PRACTICAL) 
Study, 1992-93, New Zealand (38)
Design: Randomised, double-blind, placebo-controlled, 
parallel.
Diagnosis: Within 24 hours of myocardial infarction.
Number of Subjects:
- captopril group 75
- enalapril group 75
- placebo group 75
Subject Characteristics:
* Males
- captopril group 56 (75%)
- enalapril group 59 -(79%)
- placebo group 58 (77%)
Mean Age (Years)
- captopril group 64
- enalapril group 63
- placebo group 64
Age > 70 years
- captopril group 17 (23%)
- enalapril group 21 (28%)
- placebo group 20 (27%)
* Relatively unselected in regard to degree of heart 
failure
* Thrombolytic Therapy
- captopril group 51 (68%)
- enalapril group 56 (75%)
- 102-
- placebo group 55 (73%)
* Excluded if persistent hypotension with systolic blood 
pressure < 90 mmHg, or haemodynamically significant 
valvular stenosis.
ACE Inhibitor Treatment:
* Either oral captopril 6.25 mg at 2-hour intervals for 
3 doses followed by 25 mg three times daily, or oral 
enalapril 1.25 mg at 2-hour intervals for 3 doses 
followed by 5 mg three times daily.
Duration: 12 months
Endpoints: total mortality, cardiovascular mortality 
Results: Intention-to-treat analysis
* Total Mortality
'
Captopr Enalapr Placebo Odds Ratio wrt 
Placebo (95% Cl)
Captopr Enalapr
3 mths 
follow­
up
9/75
(12.0%)
1/75
(1.3%)
7/75
(9.3%)
1.32 0.13
12 mths 
follow­
up
10/75
(13.3%)
2/75
(2.7%)
12/75
(16.0%)
0.81
(0.33-
1.99)
0.21
(0.07-
0.63)
- 103-
* Cardiovascular Mortality
Captopr Enalapr Placebo Odds Ratio wrt 
Placebo (95% Cl)
Captopr Enalapr
3 mths 
follow­
up
8/75
(10.7%)
1/75
(1.3%)
7/75
(9.3%)
1.16 0.13
12 mths 
follow­
up
8/75
(10.7%)
1/75
(1.3%)
12/75
(16.0%)
0.63
(0.25-
1.62)
0.16
(0.05-
0.49)
* Survival Analysis (survival curves p.1185): Kaplan- 
Meier estimates of survival curves showed a 
significantly better survival in the enalapril group 
compared to the other groups at 3 months and 12 months:
Three months: Mantel-Cox chi-square 6.52, df=2; p=0.038
Twelve months: Mantel-Cox chi-square 7.67, df=2;
p=0.022.
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Ambrosloni, E et al. Early Treatment of Acute Myocardial 
Infarction with Angiotensin-Converting Enzyme 
Inhibition: Safety Considerations (SMILE Pilot Study), 
1991, Italy (41)
Design: Randomised, open-label, placebo-controlled.
Diagnosis: Within 24 hours of the onset of symptoms of 
myocardial infarction (av 13.7h zofenopril, 12.4h 
placebo).
Number of Subjects:
- zofenopril group 101
- placebo group 103
Subject Characteristics:
* Males
- zofenopril group 88 (86.3%)
- placebo group 84 (81.6%)
* Mean Age(Yrs)
- zofenopril group 60.7(sd 9)
- placebo group 61.1(sd 8)
* Heart Failure (Mean Ejection Fraction)
- zofenopril group 44%
- placebo group 45%
* Killip Class > 1
- zofenopril group 18.8%
- placebo group 18.2%
* No thrombolytics
* No persistent hypotension (systolic blood press < 100 
mmHg)
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ACE Inhibitor Treatment: zofenopril calcium orally
* Initially 7.5 mg in two divided doses, then increased 
to 15-30 mg as tolerated
Duration: 12 months
Endpoint: cardiovascular mortality
Results: Intention-to-treat analysis
Cardiovascular Mortality
Zofenopril Placebo Odds Ratio 
(95% Cl)
8/101
(7.9%)
11/103
(10.7%)
0.72
(0.28-1.85)
- 106-
Ambrosionl,E et al. Survival of Myocardial Infarction 
Long-Term Evaluation (SMILE) Study, 1991-92, Italy (25)
Design: Randomised (in blocks), double-blind, placebo- 
controlled, parallel.
Diagnosis: Within 24 hours (av 15 hours in both groups) 
of the onset of anterior myocardial infarction.
Number of Subjects:
- zofenopril group 772
- placebo group 784
Subject Characteristics:
* Males
- zofenopril group 72%
- placebo group 73%
* Mean Age(Yrs)
- zofenopril group 63.9
- placebo group 64.3
* Age > 70 Yrs
- zofenopril group 29%
- placebo group 31%
* Heart Failure (Killip Class>l)
- zofenopril group 15%
- placebo group 14%
* No thrombolytics
* No persistent hypotension (sys blood pressure < 100 
mmHg)
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ACE Inhibitor Treatment: zofenopril calcium orally
* Initially 7.5 mg, repeated after 12 hours
* Subsequently progressively doubled until the target 
dose of 30 mg twice daily was reached.
Duration: 6 weeks
Endpoints: total mortality and cardiovascular mortality 
after 12 months follow-up.
Results: Intention-to-treat analysis
* Total Mortality
Zofenopril Placebo Risk Reduction! 
(95% Cl)
6 Weeks 50/772
(6.5%)
65/784
(8.3%)
25 (-12-48) 
p=0.17
One year 77/772
(10.0%)
111/784
(14.1%)
29 (6-51)
p=0.01
* Cardiovascular Mortality
Zofenopril Placebo Risk Reduction 
(95% Conf Int)%
6 Weeks 48/772
(6.2%)
63/784
(8.0%)
22 (-8-53)
p=0.08
One year ns ns ns
ns: not stated.
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* Survival Analysis
Survival curve to 12 months provided - Fig 2, p.83.
* Sub-Group Analysis - Death or Severe Congestive Heart 
Failure1 (1 year follow-up)
Zofenopril Placebo Relative Risk
(95% Cl)
All 55/772 83/784 0.67 (0.46-0.92)
Subj ects (7.1%) (10.6%) p=0.018
Male 28/557 47/571 0.59 (0.36-0.95)
(5.0%) (8.2%)
Female 27/215 36/213 0.70 (0.40-1.21)
(12.5%) (16.9%)
Age<65 yr 15/378 22/389 0.68 (0.35-1.34)
(4.0%) (5.6%)
Age>=65 40/394 61/395 0.61 (0.40-0.93)
yr (10.2%) (15.4%)
1. At least three of: third heart sound, bilateral 
pulmonary rales, pulmonary congestion on X-ray, 
peripheral oedema despite digoxin, diuretics- and 
vasodilators other than ACE inhibitors and necessitating 
open-label ACE inhibitor.
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Fourth International Study of Infarct Survival (ISIS-4) 
Pilot, 1988-91, UK and Poland (23)
Design: Randomised, open-label, placebo-controlled. 
There were three phases:
1. 3-way study. Subjects were randomised to either 
captopril, controlled-release isosorbide-5-mononitrate 
(mononitrate) or placebo.
2. 2x2 factorial study. Half of all the subjects were
randomised to captopril and the other half to captopril
placebo. Half the subjects were also randomised to
mononitrate and half to mononitrate-placebo.
3. 2x2x2 factorial study. Subjects were randomised as
per phase 2 and then two-thirds of all subjects were
randomised to intravenous 
third to matching placebo
magnesium sulphate and one-
Diagnosis: Phase 1 Phase 2/3
Suspected acute within 36h within 24h
myocardial infarction (av 16h) (av llh)
Number of Subjects: Phase 1 Phase 2/3
captopril group 133 237
placebo group 134 237
Subject Characteristics: Phase 1 Phase 2/3
* Males captopril 78% 77%
placebo 82% 76%
* Av Age captopril 61 59
(Yrs) placebo 62 60)
-  110-
Subject Characteristics: 
(cont)
Phase 1 Phase 2/3
* Thrombo- captopril 88% 61%
lytics placebo 88% 58%
* Heart captopril 35%x 19%x
Failure placebo 35%x 19%1
Note 1. The percentage for all subjects (captopril and 
placebo) but not the captopril-placebo break-up was 
available; thus, it was assumed that the percentages 
were the same in each group.
(oral)
Phase 2/3 
6.25 mg,
12.5 mg 2h later,
25 mg 8-12h 
50 mg bd
Duration: 28 days 
Endpoint: total mortality
ACE Inhibitor Treatment: captopril
Phase 1
* Initial 6.25 mg,
12.5 mg 2h later
then
Subsequent 12.5 mg tid
Results: Intention-to-treat analysis
Total Mortality
Captopril Placebo Odds Ratio 
(95% Cl)
Phase 1 3/133 5/134 0.60
(2.3%) (3.7%) (0.15-2.46)
Phase 2/3 21/237 14/237 1.54
(8.9%) (5.9%) (0.77-3.06)
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Fourth International Study of Infarct Survival (ISIS-4), 
1991-94, 31 Countries (37,45-47)
Design: Randomised (2x2x2 factorial), open-label, 
placebo-controlled.
Diagnosis: Up to 24 hours (median 8 hours) after the 
onset of suspected acute myocardial infarction
Number of Subjects:
- captopril group 29,028
- placebo group 29,022
Subject Characteristics:
* Males: 74% (group break-up not provided)
* Mean Age (Years)
not stated
* Age > 70 years: 28% (group break-up not provided)
* Clinical Heart Failure: 14% (group break-up not 
provided)
* Hypotension
- systolic blood pressure < 100 mmHg: 2%
- no cardiogenic shock or persistent severe
hypotension
* Thrombolytic Therapy: 70%
ACE Inhibitor Treatment: captopril
* Initially 6.25mg orally daily
* 12.5 mg 2 hours later, 25 mg 10-12 hours later and
- 112-
then titrated up to 50 mg twice daily 
Duration: 28 days 
Endpoint: total mortality 
Results: Intention-to-treat analysis
The other study treatments (mononitrate and magnesium) 
did not alter the results obtained with captopril.
* Total Mortality
Follow-
Up
Deaths (%) 
Captopril Placebo
Odds Ratio 
(95% Cl)
Absolute 
Risk Reduction 
(lives saved per 
1,000 patients)
5 weeks 7.19 7.69 0.93
(0.87-0.99)
4.9 (sd 2.2)
6 mths 9.87 10.53 0.93 (Cl: 
insuff info)
6.6 (sd 2.6)
12 mths 11.99 12.53 0.95
(0.91-1.00)
5.4 (sd 2.8)
Note: 5-week mortality is based on simple comparison of 
percentages whereas 6-month and 12-month mortality are 
based on a time-to-death comparison using the log rank 
method.
* Sub-Group Analysis of Mortality (at 5 weeks)
Captopril Placebo Odds Ratio 
(95% Cl)
All 2088/29028 2231/29022 0.93 (0.87-0.99)
Subj ects (7.19%) (7.69%) p = 0 .02
M a l e 1267/21518 1384/21525 0.91
(5.9%) (6.4%) not sig
Female 820/7504 844/7496 0.97
(10.9%) (11.3%) not sig
A g e < 6 0  yr 293/11699 350/11706 0.83
(2.5%) (3.0%) not sig
A g e  60-69 610/9313 705/9294 0.85
yr (6.5%) (7.6%) sig at p = 0 . 0 5
A g e  70+ 1182/8002 1176/7998 1.01
yr (14.8%) (14.7%) not sig
Sys BP 96/674 83/667 1.17
<100 m m H g (14.2%) (12.4%) not sig
Heart 585/4029 645/4041 0.89
Failure (14.5%) (16.0%) not sig
T h r ombo- 1284/19917 1387/19783 0.91
lytics (6.4%) (6.9%) not sig
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Acute Infarction Ramipril Efficacy (AIRE) Study, 1991- 
92, UK, Sweden, Ireland, South Africa, Argentina, 
Netherlands, Belgium, Germany, Denmark, Austria, 
Finland, Italy, Luxembourg, Switzerland (35)
Design: Randomised, double-blind, placebo-controlled, 
parallel. Randomisation was in blocks of 10 patients and 
stratified by centre.
Diagnosis: 3-10 days after myocardial infarction (av 5.4 
days in both groups)
Number of Subjects:
- ramipril group 1,014
- placebo group 992
Subject Characteristics:
* Males
- ramipril group 73%
- placebo group 74%
* Mean Age (Years)
- ramipril group 64.9 (sd 10.8)
- placebo group 65.1 (sd 10.8)
* Age > 70 years
not stated
* Thrombolytics
- ramipril group 59%
- placebo group 56%
* Degree of left ventricular dysfunction - clinical 
evidence of heart failure, defined by:
evidence of left ventricular failure (pulmonary 
venous congestion with interstitial or alveolar
- 115-
oedema on at least one chest X-ray), or 
evidence of pulmonary oedema (bilateral post- 
tussive crackles extending at least one-third of 
the way up the lung fields in the absence of 
chronic pulmonary disease, or
auscultatory evidence of a third heart sound with 
persistent tachycardia.
* No severe heart failure (breathlessness on talking or 
undressing not attributable to primary pulmonary 
pathology and unresponsive to non-ACE inhibitor 
treatment, usually NYHA grade IV), or heart failure of 
primary valvular or congenital aetiology.
ACE Inhibitor Treatment: ramipril orally
* Initially 1.25-2.5 mg daily
* Increased gradually to a maximum of 5 mg twice daily
Duration: 15 months (average), 6 (minimum); maximum not
stated.
Endpoint: total mortality
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Results (Intention-to-Treat): 
* Total Mortality
Ramipril Placebo Risk Reduction! 
(95% Cl)
All
Subj ects
170/1004
(17%)
222/982
(23%)
27 (11-40)
p=0.002
Age <= 64 
years
ns ns 0.95 rel hazard
Age > 64 
years
ns ns 0.65 rel hazard
Male ns ns 0.75 rel hazard
Female ns ns 0.70 rel hazard
ns: not stated.
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Chlnese Cardiac Study (CCS-1), 1990-95, China (6)
Design: Randomised, placebo-controlled, parallel; 
blinding not stated.
Diagnosis: Within 36 hours of suspected myocardial 
infarction.
Number of Subjects:
- captopril group 6814
- placebo group 6820
Subject Characteristics:
* Age/Sex break-up not stated
* Relatively unselected in regard to degree of heart 
failure
* Thrombolytic Therapy - 27%
* Excluded if persistent hypotension with systolic blood 
pressure < 90 mmHg, or chronic use of large doses of 
diuretics.
ACE Inhibitor Treatment: captopril orally
* Initially 6.25 mg
* 12.5 mg 2 hours later, then 12.5 mg three times daily. 
Duration: 1 month
Endpoint: total mortality
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Results (Intention-to-Treat):
* Total Mortality (at one month)
C a p t o p r i l P l a c e b o O d d s  R a t i o  
(95% Cl)
A b s o l u t e  R i s k  
R e d u c t i o n  
(lives s a v e d  
p e r  1 , 0 0 0  
p a t i e n t s )
6 1 7 / 6 8 1 4
(9.051)
6 5 4 / 6 8 2 0
(9.59%)
0.94
(0.84-1.05) 
p = 0 .3
5.3 (sd 5.0)
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Trandolapril Cardiac Evaluation (TRACE) Study, 1990-94, 
Denmark (48,49)
Design: Randomised, double-blind, placebo-controlled. 
Diagnosis: Within 3 to 7 days of myocardial infarction.
Number of Subjects:
- trandolapril group 876
- placebo group 873
Subject Characteristics:
* Mean age 67.3 years (group break-up not given)
* Male subjects(%): 67.2 (group break-up not given)
* Wall motion index <= 1.2 (approximates to a left 
ventricular ejection fraction <= 35%)
* Subjects with "heart failure"(%): 18.7 (group break-up 
not given and "heart failure" not defined)
* Thrombolytic Therapy - 45% (group break-up not given)
* Subjects with residual ischaemia were not excluded; 
however, subjects were excluded if an open test dose of 
0.5 mg trandolapril was not tolerated.
ACE Inhibitor Treatment: trandolapril orally
* Initially 1 mg daily for 2 days
* If tolerated, the dose was increased to 2 mg orally 
daily on the third day after randomisation and then 4 mg 
orally daily after 4 weeks.
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Duration; 4 years 
Endpoint: total mortality
Results (Intention-to-Treat): Total Mortality (at 4 
years)
Trandolapril Placebo Odds Ratio 
(95% Cl)
Absolute Risk 
Reduction 
(lives saved 
per 1,000 
patients)
307/876
(35.1%)
366/873
(41.9%)
0.78
(0.67-0.91) 
p=0.00065
68.7
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APPENDIX III. MODEL DIAGNOSTICS. MODELS FOR DEATH (ALL CAUSES)
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